var title_f18_34_18976="Papilla extruding mucus";
var content_f18_34_18976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papilla extruding mucus in a patient with IPMN",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A gaping papilla extruding mucus, pathognomonic of main-duct intraductal papillary mucinous neoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18976=[""].join("\n");
var outline_f18_34_18976=null;
var title_f18_34_18977="Vaginal tubal sterilization C";
var content_f18_34_18977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal tubal sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18977=[""].join("\n");
var outline_f18_34_18977=null;
var title_f18_34_18978="Eyebrow paucity";
var content_f18_34_18978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient eye, leprosy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Plantar ulcers and eyebrow-hair paucity. Photo Quiz. Clin Infect Dis 2006; 42:684. Copyright &copy; 2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18978=[""].join("\n");
var outline_f18_34_18978=null;
var title_f18_34_18979="Stroke in newborn with seizures";
var content_f18_34_18979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Stroke in a three day old term newborn with left-sided clonic seizures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Head CT on day of life 3 shows focal hypodensity (arrows) consistent with right MCA territory arterial ischemic stroke. Brain MRI confirms acute infarction (arrows) on axial diffusion-weighted sequences (B) and T2-weighted sequences (C). On diffusion-weighted sequences (B), subtle diffusion restriction (asterisk and dashed lines) in ipsilateral internal capsule, corpus callosum and thalamus depict foci of probable Wallerian or trans-synaptic degeneration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Ichord, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18979=[""].join("\n");
var outline_f18_34_18979=null;
var title_f18_34_18980="Azelaic acid: Patient drug information";
var content_f18_34_18980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azelaic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     see \"Azelaic acid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/30/9699?source=see_link\">",
"     see \"Azelaic acid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azelex&reg;;",
"     </li>",
"     <li>",
"      Finacea&reg;;",
"     </li>",
"     <li>",
"      Finacea&reg; Plus&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Finacea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat rosacea.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701576",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azelaic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Makeup may be used after the skin has dried.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12436 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18980=[""].join("\n");
var outline_f18_34_18980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138303\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663156\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014986\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014985\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014990\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014991\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014993\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014988\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014989\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014994\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014995\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=related_link\">",
"      Azelaic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/30/9699?source=related_link\">",
"      Azelaic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_34_18981="Guaifenesin, pseudoephedrine, and codeine: Patient drug information";
var content_f18_34_18981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin, pseudoephedrine, and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/24/41349?source=see_link\">",
"     see \"Guaifenesin, pseudoephedrine, and codeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cheratussin&reg; DAC;",
"     </li>",
"     <li>",
"      Mytussin&reg; DAC;",
"     </li>",
"     <li>",
"      Tricode&reg; GF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benylin&reg; 3.3 mg-D-E;",
"     </li>",
"     <li>",
"      Calmylin with Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2693939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to make a cough productive.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to codeine, pseudoephedrine, guaifenesin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11749 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18981=[""].join("\n");
var outline_f18_34_18981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178009\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178010\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021356\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021358\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021357\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021362\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021363\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021365\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021360\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021361\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021366\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021367\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/24/41349?source=related_link\">",
"      Guaifenesin, pseudoephedrine, and codeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_34_18982="Estimation of LV volumes";
var content_f18_34_18982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    2D echocardiographic estimation of left ventricular volumes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endocardium of the apical two and four chamber echocardiographic views in systole and diastole is traced manually. The digitized tracings are automatically calibrated and can be analysed according to a number of algorithms. In this case, the computer has analysed the orthogonal tracings according to the method of discs algorithm by dividing each image into twenty equal slices. Each slice is matched to its counterpart in the orthogonal view and each pair is extrapolated into a circular disc. This disc is stacked with the others forming a stack of coins the volume of each contributing to a sum that closely approxiamtes the volume of the chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18982=[""].join("\n");
var outline_f18_34_18982=null;
var title_f18_34_18983="Leishmania amastigote";
var content_f18_34_18983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Leishmania amastigote",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Leishmania infected white blood cell on touch imprint, Giemsa stain, 250X magnification.&nbsp; The arrow shows an amastigote with the characteristic rod-shaped kinetoplast perpendicular to the nucleus.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Naomi Aronson, MD, Walter Reed Army Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18983=[""].join("\n");
var outline_f18_34_18983=null;
var title_f18_34_18984="Somatization: Treatment and prognosis";
var content_f18_34_18984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Somatization: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18984/contributors\">",
"     Donna B Greenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18984/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18984/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/34/18984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatization is a syndrome of nonspecific physical symptoms that cannot be fully explained by a known medical condition after appropriate investigation. This syndrome has also been called \"medically unexplained symptoms,\" \"medically unexplained physical symptoms,\" \"functional somatic symptoms,\" and \"somatic symptom disorders.\" The symptoms are associated with distress and may be caused or exacerbated by anxiety, depression, and interpersonal conflicts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Somatization can be conscious or unconscious and may be influenced by a desire for the sick role or for personal gain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatization is a major public health problem that increases use of medical services independent of any accompanying psychiatric or nonpsychiatric disorder, and leads to frustration in both the patient and the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatization is seen in a number of different psychiatric disorders. These include a group of disorders, called somatoform disorders, which are described in the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/9\">",
"     9",
"    </a>",
"    ] and World Health Organization's International Classification of Diseases-10th Revision (ICD-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/10\">",
"     10",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67901 \" href=\"UTD.htm?14/20/14668\">",
"     table 1",
"    </a>",
"    ). In addition, somatization is seen in factitious disorder and malingering, which are also described in DSM-IV-TR and ICD-10. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H16#H16\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatization can be viewed as a dimensional syndrome with a spectrum of expression ranging from the exaggeration of common symptoms to unrelenting disabling symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/11\">",
"     11",
"    </a>",
"    ]. The same principles of management apply to patients across the spectrum.",
"   </p>",
"   <p>",
"    This topic reviews the treatment and prognosis of somatization. The epidemiology, pathogenesis, clinical features, and medical evaluation of somatization; diagnosis of specific disorders; and the treatment and prognosis of hypochondriasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link\">",
"     \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=see_link\">",
"     \"Hypochondriasis: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy and pharmacotherapy are each beneficial for patients with somatization. These treatments may also be combined, but there are no data to suggest which particular patients should receive both treatments. The choice of treatment depends upon availability and preferences, and the different options can be presented to the patient over time to help overcome resistance to treatment.",
"   </p>",
"   <p>",
"    Clinicians should set a goal with patients to improve occupational and interpersonal functioning. Another goal is to relieve symptoms rather than to eliminate them, in order to avoid excessive and possibly harmful treatment.",
"   </p>",
"   <p>",
"    Major depression or panic disorder are commonly comorbid in patients with somatization and should be treated with persistence. Somatization frequently resolves when the comorbid disorder is treated with appropriate pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical symptoms should be treated conservatively. A proposed method for primary care providers to manage chronic, high-utilizing patients with somatization is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=see_link\">",
"     \"Primary care management of medically unexplained symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest clinicians use the following general principles to manage patients with somatization, based upon clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Schedule regular visits",
"     </li>",
"     <li>",
"      Establish a collaborative, therapeutic alliance with the patient",
"     </li>",
"     <li>",
"      Acknowledge and legitimize symptoms",
"     </li>",
"     <li>",
"      Communicate with other clinicians",
"     </li>",
"     <li>",
"      Evaluate for and treat diagnosable medical disease",
"     </li>",
"     <li>",
"      Limit diagnostic testing and referrals to specialists",
"     </li>",
"     <li>",
"      Reassure that grave medical diseases have been ruled out",
"     </li>",
"     <li>",
"      Assess and treat the patient for psychiatric disorders",
"     </li>",
"     <li>",
"      Educate patients about coping with physical symptoms",
"     </li>",
"     <li>",
"      Explicitly set the goal of treatment as functional improvement",
"     </li>",
"     <li>",
"      Evaluate and treat substance abuse and addiction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A key part of management is to regularly schedule outpatient visits with the primary care clinician, so that symptoms are not required for the patient to receive clinical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/13\">",
"     13",
"    </a>",
"    ]. This is less stressful for the patient and clinician than symptom-driven visits, avoids reinforcing the sick role, and enables the clinician to provide reassurance on the basis of focal physical examinations and to remain vigilant for the same diseases that can befall any patient. The visit interval depends upon the individual patient. The goal is to find the right interval that avoids inappropriate emergency visits or telephone calls. It is reasonable to initially try monthly visits. Patients should be discouraged from going to the emergency department before consulting with their primary clinician since this often leads to a litany of unnecessary and costly tests.",
"   </p>",
"   <p>",
"    Crises must be managed firmly so that the multiple chronic or recurrent symptoms do not elicit excessive evaluation. The clinician must be supportive but firm, and adhere to the agreed upon schedule of visits for recurrent problems.",
"   </p>",
"   <p>",
"    Clinicians should emphasize functioning and coping [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/2\">",
"     2",
"    </a>",
"    ]. The focus of treatment should be the restoration and maintenance of functioning at work, home and in social circles through rehabilitation. Clinicians should encourage patients to take an active role in treatment by working on specific, realistic, incremental goals that include observable behaviors. This will help to discourage patients from assuming the sick role. One example of a useful treatment plan is a graduated exercise program.",
"   </p>",
"   <p>",
"    Specific treatment recommendations depend upon the extent of the patient's illness belief and degree of impairment. Some patients will be interested only in specific treatment for a specified disorder or symptom management, such as antidepressant medication. Other patients may be receptive to entering a formal behavior modification program to improve their social and occupational functioning.",
"   </p>",
"   <p>",
"    It is common for patients with somatization to consult one doctor after another (\"doctor shopping\"). Thus, communication among clinicians is vital.",
"   </p>",
"   <p>",
"    When malingering is suspected (ie, somatization in order to pursue a tangible benefit such as Workers Compensation in the United States), it is important to understand the motivations for symptom production to manage these patients. We suggest confronting the individual in a manner that allows him or her to save face. As an example, the clinician may state, \"Your symptoms are not consistent with a known illness and I wonder if there is another reason for them\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To engage the patient in treatment, metaphors can be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/13\">",
"     13",
"    </a>",
"    ]. The symptoms, which are not amenable to medical or surgical intervention, can be compared to a radio channel that cannot be changed. The patient needs to gain greater control over the volume knob and the sensitivity of the antenna (ie, factors that increase or decrease symptoms).",
"   </p>",
"   <p>",
"    Not all patients are ready for treatment. Clinicians may find that some patients adamantly believe their symptoms are caused by a nonpsychiatric medical condition and refuse to work with clinicians who do not confirm this belief. We suggest clinicians take a long-term perspective and let such patients know that the clinician is always available to provide treatment when the patient is ready.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Structure of visits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caring for patients with somatization requires time to listen to the patients. This should occur at regularly scheduled office visits not contingent upon complaint, so that patients can voice concerns without feeling the need to make telephone calls or emergency visits.",
"   </p>",
"   <p>",
"    New symptoms and current stressors should be explored at these visits. Familiarity with the patient allows judicious evaluation of new symptoms. It is important to remember that the patient with somatization, as with all patients, remains at risk for developing new and potentially serious medical conditions. After treatable medical conditions are excluded, clinicians can express empathy for the patient's predicament, and shift the focus away from the physical symptoms and toward the social situation in which new symptoms occur.",
"   </p>",
"   <p>",
"    A physical examination should be performed at each visit, at least in the initial period of patient management [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/4\">",
"     4",
"    </a>",
"    ]. It may be tempting to use diagnostic tests and specialty consultations for the sole purpose of reassuring the patient; however, procedures may cause additional complications and negative findings rarely provide lasting reassurance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/5\">",
"     5",
"    </a>",
"    ]. A study of 420 audiotaped general practice consultations with patients with unexplained symptoms revealed that doctors were more likely to propose physical interventions than respond to patient cues about psychological needs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of controlled trials support the use of antidepressant medication to treat somatoform disorders and medically unexplained symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A meta-analysis of 94 controlled trials of antidepressants found a large benefit for treating unexplained symptoms and symptom syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in patients occurred more than three times as often with antidepressants compared with placebo (OR 3.4, 95% CI 2.6-4.5).",
"     </li>",
"     <li>",
"      Treatment of approximately three patients with antidepressants yielded a beneficial response in one additional patient that would not have occurred with placebo (number needed to treat of three).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The meta-analysis found tricyclic antidepressants were beneficial in treating somatization in significantly more studies compared with selective serotonin reuptake inhibitors (76 versus 47 percent of studies), but there was an insufficient number of trials of selective serotonin reuptake inhibitors to draw a firm conclusion about the relative efficacy of the two classes of antidepressants. In addition, 50 of the 94 trials involved patients with chronic headache, and tricyclics are beneficial for these patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of chronic daily headache\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic migraine\", section on 'Management'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors are beneficial for treating the specific somatoform disorders hypochondriasis and body dysmorphic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=see_link&amp;anchor=H4695045#H4695045\">",
"     \"Hypochondriasis: Treatment and prognosis\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    St. John's wort has been shown to be efficacious for treating somatoform disorders independent of any existing depression, and also well tolerated and safe. Use of St. John's wort is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical use of St. John's wort\", section on 'Somatoform disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychotropic agents should be initiated at low doses in patients with somatization and increased slowly as tolerated to achieve a therapeutic dose. A typical antidepressant regimen should start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    20 mg per day or another selective serotonin reuptake inhibitor in the morning, titrating the dose every four weeks as needed and tolerated, in order to minimize side effects. These side effects may become another source of complaint. Alternatively, it is reasonable to start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    25 mg at bedtime, titrating the dose up every four weeks as needed and tolerated. One report suggests that adding a low dose antipsychotic may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with somatization may resist taking \"chemicals\" to treat their psychiatric disorders and others will report intolerance to relatively low levels of medication.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     Nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    are available as a 10 mg pill for patients vulnerable to side effects.",
"   </p>",
"   <p>",
"    Symptoms of somatization, depression, and anxiety should be reassessed regularly, to evaluate the response to medication and adjust the dose as needed. Clinicians should also monitor compliance with medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should avoid opioid analgesics or other potentially addictive medications as much as possible.",
"   </p>",
"   <p>",
"    A meta-analysis of 11 randomized trials treating patients with somatoform pain disorder and psychogenic pain found antidepressants decreased pain intensity significantly more compared with placebo, and the clinical effect size was moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/18\">",
"     18",
"    </a>",
"    ]. A second meta-analysis of 39 randomized trials found antidepressants were efficacious in treating chronic nonmalignant pain, with a moderate to large clinical effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antidepressants that act upon both noradrenergic and serotonergic receptors, such as tricyclics and serotonin-norepinephrine reuptake inhibitors, may have more analgesic effects than other antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/16,19-23\">",
"     16,19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic pain and depression benefit from any form of depression treatment. An observational study found that individuals with chronic pain and depression who received any depression treatment were significantly less likely to report that pain interfered with their work compared to those who received no treatment (OR 0.57, 95% CI 0.34-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of controlled trials for treating various pain syndromes found adjunctive neuroleptic added to a tricyclic antidepressant was not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of chronic pain due to a general medical condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider psychotherapy to treat somatization, especially cognitive behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/25-33\">",
"     25-33",
"    </a>",
"    ]. Other psychotherapies include family therapy, psychoeducation, supportive therapy, stress management, and psychodynamic psychotherapy. These can all be provided individually or in a group format, and may be provided in a primary care or psychiatric setting.",
"   </p>",
"   <p>",
"    Guidelines for short-term treatment of patients with somatization include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clearly explain the structure of the treatment plan",
"     </li>",
"     <li>",
"      Teach meaningful skills relevant to daily life",
"     </li>",
"     <li>",
"      Training in these skills should continue until they are mastered in the therapist's office",
"     </li>",
"     <li>",
"      Patients need to practice these skills outside of the office",
"     </li>",
"     <li>",
"      Clinicians should attribute improvement to the patient's increased skills",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of psychotherapy to treat hypochondriasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=see_link&amp;anchor=H4695003#H4695003\">",
"     \"Hypochondriasis: Treatment and prognosis\", section on 'Psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should consider cognitive behavioral therapy (CBT) to treat somatization because the evidence supporting CBT is stronger than it is for any other psychotherapy.",
"   </p>",
"   <p>",
"    Systematic reviews consistently find CBT is efficacious for treatment of somatoform disorders and medically unexplained symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a review of 13 controlled CBT trials for treatment of somatoform disorders, CBT was beneficial in 85 percent of the trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/7\">",
"     7",
"    </a>",
"    ]. In a second review of 31 controlled trials of CBT, physical symptoms appeared to be more responsive to therapy than did psychologic distress and functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/35\">",
"     35",
"    </a>",
"    ]. The median number of treatment sessions was eight, and benefits achieved by the end of treatment persisted for up to 24 months. Group CBT was as efficacious as individual CBT.",
"   </p>",
"   <p>",
"    CBT directs patients to reexamine their health beliefs and expectations, and to look at how the sick role affects their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/2\">",
"     2",
"    </a>",
"    ]. Behavioral techniques are used to improve role functioning and minimize sick role behaviors. These techniques include response prevention, systematic desensitization, progressive muscle relaxation, and graduated exercise programs. A practical guide for providing CBT is shown (",
"    <a class=\"graphic graphic_table graphicRef66467 \" href=\"UTD.htm?25/47/26365\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/3,36\">",
"     3,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary care providers have successfully provided CBT to patients with somatization. In one study, patients were randomly assigned to group CBT or a control group waiting list, and general practitioners administered eight weekly sessions of CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/37\">",
"     37",
"    </a>",
"    ]. Each three-hour session consisted of an educational lesson explaining stress and coping, followed by a general discussion and then relaxation training. Patients who received CBT showed significantly more improvement than controls six months post treatment in the perception of their illness, somatic preoccupation, hypochondriasis, and use of medications. There were no significant differences in depression, anxiety, sleep quality, or perception of social problems.",
"   </p>",
"   <p>",
"    The use of CBT is limited when a patient is unable to rationally discuss cognitive distortions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Family therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several reasons to involve family members in treatment. Family members can help clinicians better understand the patient's symptoms and social structure. In addition, genuine concern leads family members to unintentionally reinforce the patient's problematic behaviors. Difficulties with specific family functions and processes such as communication and problem solving may also exacerbate the patient's illness. Family members may be struggling to cope with the patient's illness and may require help for themselves.",
"   </p>",
"   <p>",
"    Family therapy has not been studied in a systematic fashion for the treatment of somatization.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H158682533#H158682533\">",
"     \"Overview of psychotherapies\", section on 'Family therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Psychoeducation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education is effective for treating patients. In one study, primary care clinicians treating 70 patients with somatization disorder all received a consultation letter offering treatment recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients were randomly assigned to receive eight group therapy sessions focused on education or to treatment as usual. The experimental group reported significantly better physical and mental health, and generated 52 percent less healthcare costs over a one-year period. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Psychiatric referral'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychiatric referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care clinicians suspecting somatization should consider sending their patients to a psychiatrist for a one-time consultation. A systematic review of six randomized trials (449 patients with somatization) compared a consultation letter (from a psychiatrist to the primary care clinician) with treatment as usual, and found that the letter reduced the severity of symptoms, improved physical and social functioning, and reduced medical costs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/39\">",
"     39",
"    </a>",
"    ]. For patients diagnosed with somatization or a specific somatoform disorder, the consultation letter describes the diagnosis and prognosis, and makes the following recommendations for management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tell patients that their symptoms are taken seriously",
"     </li>",
"     <li>",
"      Avoid describing symptoms as entirely psychogenic (&ldquo;all in your head&rdquo;)",
"     </li>",
"     <li>",
"      Avoid further referrals and laboratory tests unless there is a clear indication of a general medical disorder",
"     </li>",
"     <li>",
"      Schedule regular visits",
"     </li>",
"     <li>",
"      Perform a physical exam at each visit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the primary care clinician remains the responsible caregiver, and the psychiatrist's advice reduces diagnostic uncertainty and potentially harmful procedures and interventions.",
"   </p>",
"   <p>",
"    Primary care clinicians may decide to refer patients with somatization to a mental health clinician for other reasons. A mental health specialist can help establish the diagnosis of a comorbid depressive and anxiety disorder. In addition, most primary care clinicians do not have the time or training to provide specific treatments such as cognitive behavioral therapy or family therapy.",
"   </p>",
"   <p>",
"    Some patients will resist a psychiatric referral. The clinician should offer the referral in such a way that the patient does not feel stigmatized or dismissed. The patient's willingness to accept a psychiatric referral will likely depend upon the patient's conviction that the referring clinician will not abandon him or her.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of controlled trials for treatment of somatoform disorders and medically unexplained symptoms have found evidence to support using other interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These include training primary care clinicians to manage somatizing patients and using a nurse care intervention.",
"   </p>",
"   <p>",
"    In addition, a controlled trial compared aerobic exercise versus stretching for primary care patients with somatization, and found both were helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/40\">",
"     40",
"    </a>",
"    ]. Each intervention included 20 group sessions, each session lasting one hour. Both forms of exercise led to a significant reduction in the number of physical symptoms, clinician visits, and medication prescriptions at six-month follow-up, compared with baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of illness in patients with the specific types of somatization described in DSM-IV-TR and ICD-10 are often chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, effective treatment of depressive or anxiety disorders makes a difference. Even when the course is chronic, it is possible for clinicians to develop and maintain relationships with patients, and help them to improve their psychosocial functioning and rely less upon diagnostic tests, medications, consults, and treatment by medical specialists.",
"   </p>",
"   <p>",
"    Some patients with somatization improve over the short-term [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/41\">",
"     41",
"    </a>",
"    ]. A systematic review of medically unexplained symptoms found that 50 to 75 percent of patients improved or even recovered during follow-up lasting 6 to 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/42\">",
"     42",
"    </a>",
"    ]. A subsequent study of 32 primary care patients with somatization defined as three or more bothersome, medically unexplained symptoms found that after five years, 78 percent no longer met criteria for the condition, although it is not clear how many still had one or two bothersome symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DSM-IV-TR and ICD-10 describe the specific diagnoses of hypochondriasis and somatization disorder as chronic but fluctuating conditions that remit only occasionally [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Systematic reviews have found that improvement and even remission from hypochondriasis and somatization disorder does occur in short-term studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. One review found that between 33 to 85 percent of patients with hypochondriasis no longer met criteria for the disorder in studies that mostly lasted approximately one year or less. In another review, more than 50 percent of patients with somatization disorder no longer met criteria over a one-year period. However, it's important to note that simply because a patient no longer meets criteria for these disorders, that does not mean all symptoms have completely and permanently resolved. In addition, patients may well again meet criteria for the disorder at a subsequent time point.",
"   </p>",
"   <p>",
"    Conversion disorder can also be chronic. A study of 42 patients with presumptive conversion disorder followed for a median duration of 12.5 years found unilateral functional weakness or sensory disturbance persisted in 83 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/45\">",
"     45",
"    </a>",
"    ]. Only one patient developed a neurologic disorder that explained the presenting symptoms.",
"   </p>",
"   <p>",
"    A few prognostic factors have consistently been identified across different studies. Two systematic reviews both found improvement in somatization was more likely in patients with fewer physical symptoms and better functioning at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18984/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. These predictors are nonspecific and similar to the factors that predict improvement of other psychiatric disorders. The reviews found other nonspecific factors associated with improvement of somatization included less pain, anxiety, and depression at baseline.",
"   </p>",
"   <p>",
"    There are no data on the rate of recurrence among patients who recover from somatization. It is our experience that even when symptoms improve or even remit, other symptoms may arise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatization is a syndrome of physical symptoms that cannot be fully explained by a known medical condition after appropriate investigation. The symptoms are associated with distress and may be caused or exacerbated by anxiety, depression, and interpersonal conflicts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Principles for managing somatization, based upon clinical experience, include scheduling regular visits, acknowledging symptoms, communicating with other clinicians, assessing and treating diagnosable medical and psychiatric disorders, limiting tests and referrals, reassuring the patient that grave medical diseases have been ruled out, and making functional improvement the goal of treatment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with somatization often have comorbid depressive and anxiety disorders. Somatization frequently resolves when these psychiatric syndromes are appropriately treated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacotherapy and psychotherapy are each beneficial, and there is no evidence to indicate one is better than the other. The choice of treatment, including the combination of pharmacotherapy and psychotherapy, depends upon availability and preferences. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When pharmacotherapy is selected for the treatment of somatoform disorders, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      20 mg per day or another selective serotonin reuptake inhibitor in the morning, titrating the dose every four weeks as needed and tolerated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatively, it is reasonable to start with a tricyclic antidepressant such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      25 mg at bedtime, titrating the dose up every four weeks as needed and tolerated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of somatoform pain disorder, we suggest antidepressants with both a noradrenergic and serotonergic profile (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest clinicians avoid opioids (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Pain'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For patients in whom psychotherapy is selected for the treatment of somatoform disorders, we suggest cognitive behavioral therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A practical guide for providing CBT is shown (",
"      <a class=\"graphic graphic_table graphicRef66467 \" href=\"UTD.htm?25/47/26365\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a one-time psychiatric referral as an effective intervention for patients with somatization (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The referral can clarify the diagnosis and its nonlethal nature, and make specific recommendations for management, such as limiting tests. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Psychiatric referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Somatization follows a chronic and fluctuating course. Short-term studies show that 50 percent or more of patients improve and no longer meet criteria for a specific type of disorder, but this is not the same thing as complete and permanent resolution of all medically unexplained symptoms. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Yutzy SH, Parish BS. Somatoform disorders. In: The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed, Galanter M, Kleber HD.  (Eds), American Psychiatric Publishing, Washington, DC 2008. p.609.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/2\">",
"      Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med 1999; 130:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/3\">",
"      Bornschein S, F&ouml;rstl H, Zilker T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/4\">",
"      Epstein RM, Quill TE, McWhinney IR. Somatization reconsidered: incorporating the patient's experience of illness. Arch Intern Med 1999; 159:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/5\">",
"      Barsky AJ. Clinical practice. The patient with hypochondriasis. N Engl J Med 2001; 345:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/6\">",
"      Ring A, Dowrick CF, Humphris GM, et al. The somatising effect of clinical consultation: what patients and doctors say and do not say when patients present medically unexplained physical symptoms. Soc Sci Med 2005; 61:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/7\">",
"      Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/8\">",
"      Sumathipala A. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosom Med 2007; 69:889.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. Available online at: www.who.int/classifications/apps/icd/icd10online/ (Accessed on December 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/11\">",
"      Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psychiatry 1991; 148:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/12\">",
"      Keeley R, Smith M, Miller J. Somatoform symptoms and treatment nonadherence in depressed family medicine outpatients. Arch Fam Med 2000; 9:46.",
"     </a>",
"    </li>",
"    <li>",
"     Abbey SE, Wulsin L, Levenson JL. Somatization and somatoform disorders. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, American Psychiatric Publishing, Inc., Washington, DC 2011. p.261.",
"    </li>",
"    <li>",
"     McDermott BE, Leamon MH, Feldman MD, Scott CL. Factitious disorder and malingering. In: he American Psychiatric Publishing Textbook of Psychiatry, 5th ed, Hales RE, Yudofsky SC, Gabbard GO.  (Eds), American Psychiatric Publishing, Washington, DC 2008. p.643.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/15\">",
"      O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/16\">",
"      Fallon BA. Pharmacotherapy of somatoform disorders. J Psychosom Res 2004; 56:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/17\">",
"      Huang M, Luo B, Hu J, et al. Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. Int Clin Psychopharmacol 2012; 27:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/18\">",
"      Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med 1998; 60:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/19\">",
"      Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/20\">",
"      Quilici S, Chancellor J, L&ouml;thgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009; 9:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/21\">",
"      Briley M, Moret C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr 2008; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/22\">",
"      Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/23\">",
"      Pae CU, Park MH, Marks DM, et al. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs 2009; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/24\">",
"      Teh CF, Zaslavsky AM, Reynolds CF 3rd, Cleary PD. Effect of depression treatment on chronic pain outcomes. Psychosom Med 2010; 72:61.",
"     </a>",
"    </li>",
"    <li>",
"     Folks DB, Feldman MD, Ford CV. omatoform disorders, factitious disorders, and malingering. In: Psychiatric Care of the Medical Patient, 2nd ed, Stoudemire, A, Fogel, et al.  (Eds), Oxford, New York 2000. p.459.",
"    </li>",
"    <li>",
"     Smith GR. Somatization in the Medical Setting, merican Psychiatric Press Inc., Washington, DC 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/27\">",
"      Barsky AJ, Ettner SL, Horsky J, Bates DW. Resource utilization of patients with hypochondriacal health anxiety and somatization. Med Care 2001; 39:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/28\">",
"      Barsky AJ, Geringer E, Wool CA. A cognitive-educational treatment for hypochondriasis. Gen Hosp Psychiatry 1988; 10:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/29\">",
"      Hellman CJ, Budd M, Borysenko J, et al. A study of the effectiveness of two group behavioral medicine interventions for patients with psychosomatic complaints. Behav Med 1990; 16:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/30\">",
"      Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet 2007; 369:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/31\">",
"      Greeven A, van Balkom AJ, Visser S, et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry 2007; 164:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/32\">",
"      Staudenmayer H. Psychological treatment of psychogenic idiopathic environmental intolerance. Occup Med 2000; 15:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/33\">",
"      Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev 2007; :CD006520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/34\">",
"      Staudenmayer H. Clinical consequences of the EI/MCS \"diagnosis\": two paths. Regul Toxicol Pharmacol 1996; 24:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/35\">",
"      Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom 2000; 69:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/36\">",
"      Sharpe M, Peveler R, Mayou R. The psychological treatment of patients with functional somatic symptoms: a practical guide. J Psychosom Res 1992; 36:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/37\">",
"      Lidbeck J. Group therapy for somatization disorders in general practice: effectiveness of a short cognitive-behavioural treatment model. Acta Psychiatr Scand 1997; 96:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/38\">",
"      Kashner TM, Rost K, Cohen B, et al. Enhancing the health of somatization disorder patients. Effectiveness of short-term group therapy. Psychosomatics 1995; 36:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/39\">",
"      Hoedeman R, Blankenstein AH, van der Feltz-Cornelis CM, et al. Consultation letters for medically unexplained physical symptoms in primary care. Cochrane Database Syst Rev 2010; :CD006524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/40\">",
"      Peters S, Stanley I, Rose M, et al. A randomized controlled trial of group aerobic exercise in primary care patients with persistent, unexplained physical symptoms. Fam Pract 2002; 19:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/41\">",
"      Rosendal, M, Burton, C, Blankenstein, AH, et al. Enhanced care by generalists for functional somatic symptoms and disorders in primary care. Cochrane Database Syst Rev 2009; :CD008142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/42\">",
"      olde Hartman TC, Borghuis MS, Lucassen PL, et al. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. J Psychosom Res 2009; 66:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/43\">",
"      Jackson JL, Kroenke K. Prevalence, impact, and prognosis of multisomatoform disorder in primary care: a 5-year follow-up study. Psychosom Med 2008; 70:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/44\">",
"      Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 2004; 56:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18984/abstract/45\">",
"      Stone J, Sharpe M, Rothwell PM, Warlow CP. The 12 year prognosis of unilateral functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry 2003; 74:591.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7767 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18984=[""].join("\n");
var outline_f18_34_18984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Structure of visits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Family therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Psychoeducation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychiatric referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/20/14668\" title=\"table 1\">",
"      Somatization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/47/26365\" title=\"table 2\">",
"      A practical guide for using CBT to treat somatization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=related_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=related_link\">",
"      Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=related_link\">",
"      Hypochondriasis: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=related_link\">",
"      Overview of chronic daily headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=related_link\">",
"      Primary care management of medically unexplained symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_34_18985="Clinical presentation and diagnosis of dengue virus infections";
var content_f18_34_18985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of dengue virus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Alan L Rothman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Anon Srikiatkhachorn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Siripen Kalayanarooj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18985/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/34/18985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue is the most prevalent mosquito-borne viral disease; it is estimated that over 50 million dengue virus infections occur each year throughout the world [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptomatic dengue virus infections can present with a wide range of clinical manifestations, from a mild febrile illness to a life-threatening shock syndrome or organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Both viral and host factors are thought to contribute to the manifestations of disease in each infected individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The various clinical features and the available methods for the diagnosis of dengue virus infections will be reviewed here. The pathogenesis and measures to prevent and treat the disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four closely related, but serologically distinct dengue viruses, called DENV-1, DENV-2, DENV-3, and DENV-4, of the genus Flavivirus. Since there is only transient and weak cross-protection among the four serotypes, persons living in an area of endemic dengue can be infected with three, and probably four, dengue serotypes during their lifetime. Multiple virus serotypes often co-circulate within the same city (hyperendemicity), causing periodic epidemics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical clinical manifestations of dengue range from self-limited dengue fever to dengue hemorrhagic fever with shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/4\">",
"     4",
"    </a>",
"    ]. With wider availability of laboratory testing, there are increasing reports of unusual clinical manifestations as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of severe disease is much higher in sequential rather than primary dengue infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asymptomatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon experimentally induced infection in adult human volunteers, it was concluded that almost all dengue virus infections were symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/6\">",
"     6",
"    </a>",
"    ]. However, age appears to influence the prevalence of symptomatic disease. For example, in a survey of United States military personnel who served in Somalia, only 7 (14 percent) of 44 individuals with serologic evidence of dengue virus infection were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/7\">",
"     7",
"    </a>",
"    ]. By contrast, epidemiologic studies have shown that the majority of infections in children under age 15 years are asymptomatic or minimally symptomatic. For example, in one study of schoolchildren in rural Thailand, 53 percent of dengue virus infections were not associated with a recognized febrile illness despite intense active surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms typically develop between 4 and 7 days after the bite of an infected mosquito, although the incubation period may range from 3 to 14 days. Dengue can essentially be excluded as the cause of symptoms in a traveler developing an illness more than 14 days after returning from a dengue-endemic country [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dengue fever",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Classic dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic dengue fever (DF) is an acute febrile illness accompanied by headache, retroorbital pain, and marked muscle and joint pains, which evoked the term \"break-bone fever\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/10\">",
"     10",
"    </a>",
"    ]. Fever typically lasts for five to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/11\">",
"     11",
"    </a>",
"    ]. Some patients display a biphasic (\"saddleback\") fever curve, with the second febrile phase lasting one to two days, although this was reported in only 5 to 6 percent of patients in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. The febrile period may also be followed by a period of marked fatigue that can last for days to weeks, especially in adults.",
"   </p>",
"   <p>",
"    In a sample of 3926 patients with dengue from Puerto Rico [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/12\">",
"     12",
"    </a>",
"    ], the frequency of symptoms was influenced by the patient's age and sex and differed in patients with primary versus secondary dengue virus infection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    ). All symptoms were less frequent in patients 19 years of age or younger. Joint pain, body pain, and rashes were more common in females. Constitutional symptoms and gastrointestinal symptoms were more common in patients experiencing a secondary dengue virus infection, whereas rashes were more commonly noted during primary dengue.",
"   </p>",
"   <p>",
"    High frequencies of myalgia, headache, and retroorbital pain among dengue cases in the studies listed above may represent overestimates due to selection bias. Several studies of travelers or military personnel have reported these \"classic\" symptoms of DF in a range of 15 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/7,9,11,13\">",
"     7,9,11,13",
"    </a>",
"    ]. Fever and extreme fatigue have been the predominant symptoms of patients in these series. When a rash occurred, it appeared between two and five days after the onset of fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hemorrhagic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhagic manifestations occur commonly in patients with DF, and in rare cases can be life-threatening. In a large, prospective study in Thailand, spontaneous bleeding occurred in 68 percent of children with DF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/14\">",
"     14",
"    </a>",
"    ]. The main bleeding sites were the skin (58 percent) and nose (19 percent). Gastrointestinal bleeding was less common (4 percent). In a series of 18 adults who acquired DF during travel, hemorrhagic phenomena were noted in four (22 percent); two patients had purpura and two melena [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/11\">",
"     11",
"    </a>",
"    ]. This clinical presentation needs to be differentiated from dengue hemorrhagic fever, described below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Dengue hemorrhagic fever'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute dengue virus infection often presents without the full picture of classical DF, especially in children. Gastrointestinal or respiratory tract symptoms may dominate the clinical picture in some patients. Among 3926 patients with laboratory-diagnosed dengue virus infections in Puerto Rico during 1990 and 1991, one-third of whom were under age 15 years, the frequency of specific symptoms was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constitutional symptoms, including fever (90 percent) and headache, eye pain, body pain, and joint pain (63 to 78 percent)",
"     </li>",
"     <li>",
"      Rash (slightly more than 50 percent)",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms including nausea or vomiting (more than 50 percent) and diarrhea (30 percent)",
"     </li>",
"     <li>",
"      Respiratory tract symptoms including cough, sore throat, and nasal congestion (each observed in approximately one-third of patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in patients with DF is generally nonspecific. The frequencies of fever and rash are noted above. Conjunctival injection, pharyngeal erythema, lymphadenopathy, and hepatomegaly are observed in 20 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/13\">",
"     13",
"    </a>",
"    ]. The rash is typically macular or maculopapular and may be associated with pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings typical of DF include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukopenia is common in both adults and children with DF and is a useful diagnostic feature [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/13,15,16\">",
"       13,15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombocytopenia is noted in most patients with DF [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/17\">",
"       17",
"      </a>",
"      ]. In several studies platelet counts &lt;100,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were observed in 16 to 55 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum aspartate transaminase (AST) levels are frequently elevated in both adults and children with DF; the elevations are usually modest (2 to 5 times the upper limit of normal values), but marked elevations (5 to 15 times the upper limit of normal) are occasionally noted [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dengue hemorrhagic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue hemorrhagic fever (DHF) is the most serious manifestation of dengue virus infection and can be associated with circulatory failure and shock. The four cardinal features of DHF, as defined by the World Health Organization (WHO), include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/3,5,18\">",
"     3,5,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased vascular permeability (plasma leakage syndrome) evidenced by hemoconcentration (20 percent or greater rise in hematocrit above baseline value), pleural effusion, or ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Marked thrombocytopenia (100,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or lower)",
"     </li>",
"     <li>",
"      Fever lasting two to seven days",
"     </li>",
"     <li>",
"      A hemorrhagic tendency (as demonstrated by a positive tourniquet test) or spontaneous bleeding (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Hemorrhagic manifestations'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term dengue shock syndrome (DSS) is used when shock is present along with these four criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although DF and DHF are frequently referred to as quite different diseases, physicians should recognize that the WHO criteria listed above define DHF narrowly. These case definitions highlight the importance of plasma leakage as a pathophysiologic feature of severe dengue, but they do not encompass all patients with clinically severe or complicated dengue infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. The case definitions should therefore not supplant good clinical judgment in the prospective management of patients with suspected dengue. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Classification controversies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Plasma leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma leakage is the most specific and life-threatening feature of DHF. The increase in vascular permeability develops over a period of 24 to 48 hours. Shock may develop in patients with marked plasma leakage, especially if supportive treatment is delayed. This clinical presentation is referred to as \"dengue shock syndrome\" (DSS) and is associated with a case-fatality rate as high as 12 percent in some studies, even with aggressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma leakage usually occurs between three and seven days after the onset of illness. This coincides with defervescence, severe thrombocytopenia, and elevation of aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/15\">",
"     15",
"    </a>",
"    ]. Abdominal pain is also reported to precede the onset of plasma leakage in approximately 60 percent of adults and children with DHF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The presence of intense abdominal pain, persistent vomiting, and marked restlessness or lethargy, especially coinciding with defervescence, should alert the clinician to possible impending dengue shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiography and",
"    <span class=\"nowrap\">",
"     chest/abdominal",
"    </span>",
"    ultrasound are the imaging modalities useful for detection of plasma leakage in DHF. In one study of 158 suspected cases in Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/25\">",
"     25",
"    </a>",
"    ], right lateral decubitus chest x-ray was more sensitive for detection of pleural effusion, but ultrasound was successful in detecting larger effusions and had the advantages of evaluating intra-abdominal fluid and avoiding ionizing radiation. Plasma leakage was detected by ultrasound as early as three days after the onset of fever; pleural effusions were more common than ascites or edema of the gallbladder wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hemorrhagic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of hemorrhagic manifestations is quite variable among patients with DHF. Spontaneous petechiae or ecchymoses were noted in approximately one-half of adults and children with DHF in Cuba [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Other less-frequent hemorrhagic manifestations reported in these studies included: hematemesis (15 to 30 percent of subjects), menorrhagia (40 percent of adult women), melena (5 to 10 percent), and epistaxis (10 percent).",
"   </p>",
"   <p>",
"    Microvascular fragility may be demonstrated by a positive \"tourniquet test\"; this test is performed by inflating a blood pressure cuff on the arm to midway between systolic and diastolic blood pressures for five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/26\">",
"     26",
"    </a>",
"    ]. The pressure is released for at least one minute and the skin below the cuff is examined for petechiae. A finding of 10 or more petechiae in a one square inch area is considered positive.",
"   </p>",
"   <p>",
"    Hemorrhagic manifestations are also common in dengue fever [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/14,27\">",
"     14,27",
"    </a>",
"    ]; this can be severe, requiring hospitalization and transfusion in rare patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Dengue fever'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Expanded dengue syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, liver failure or central nervous system (CNS) dysfunction or both dominate the clinical picture in a patient with acute dengue virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Liver failure has been documented particularly after resuscitation from profound shock, and, in many cases, may be caused by prolonged hypoperfusion or hypoxia rather than a direct viral effect.",
"   </p>",
"   <p>",
"    Neurological manifestations that have been associated with dengue virus infection include encephalopathy and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/29,30,32,33\">",
"     29,30,32,33",
"    </a>",
"    ]. Symptoms include fever, headache, lethargy; some patients may have no characteristic features of dengue fever or dengue hemorrhagic fever on admission [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/30\">",
"     30",
"    </a>",
"    ]. The diagnosis of dengue virus has been supported by either serologic testing or viral isolation or detection by polymerase chain reaction in cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/30\">",
"     30",
"    </a>",
"    ]. Permanent neurologic sequelae have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/30,32\">",
"     30,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reye syndrome has been noted in children but may be associated with use of salicylate-containing medications rather than dengue virus infection per se. Other neurologic syndromes that have been reported to be potentially associated with dengue virus infection include acute pure motor weakness, mononeuropathies, polyneuropathies, Guillain-Barr&eacute; syndrome, and transverse myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal pain has been described as the predominant clinical feature in a small number of patients with dengue, mimicking an acute abdomen. Other disease syndromes, including myocarditis, cholecystitis, and retinal vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/34\">",
"     34",
"    </a>",
"    ], have been reported in patients in endemic countries with serologic evidence of acute dengue; however, subclinical dengue infections are common in these areas, and dengue virus infection has not been definitively established as the cause of these unusual manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CONTROVERSIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For several decades prior to 2009, the World Health Organization (WHO) classified symptomatic dengue virus infections into three categories: undifferentiated fever, classic dengue fever (DF), and dengue hemorrhagic fever (DHF). Subsequently these categories have been criticized for several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confusion arises because the term DHF suggests that hemorrhage is the cardinal manifestation, whereas plasma leakage leading to shock is the most specific feature of severe dengue and is most important for clinical management.",
"     </li>",
"     <li>",
"      Some patients with severe clinical syndromes requiring medical intervention do not meet all the criteria for DHF. &nbsp;",
"     </li>",
"     <li>",
"      Classification is difficult when patients meet some but not all four diagnostic criteria, especially if pivotal clinical laboratory data are unavailable.",
"     </li>",
"     <li>",
"      The diagnostic criteria for DHF have been inconsistently applied in epidemiologic and scientific reports.",
"     </li>",
"     <li>",
"      Reporting that is limited to DHF according to the WHO classification scheme underestimates the disease burden of dengue illness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues have been illustrated in studies among travelers and patients with documented dengue infection in endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/14,37\">",
"     14,37",
"    </a>",
"    ]. In one study of travelers, two patients (0.9 percent) fulfilled the WHO case definition for DHF, although 23 (11 percent) had what were considered severe clinical manifestations including internal hemorrhage, plasma leakage, shock, or marked thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/37\">",
"     37",
"    </a>",
"    ]. A secondary immune response was associated with both spontaneous hemorrhage and other severe manifestations of disease.",
"   </p>",
"   <p>",
"    As a result of these concerns, revised classification systems have been adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/3,38\">",
"     3,38",
"    </a>",
"    ], albeit with significant areas of divergence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The WHO Special Program for Research and Training in Tropical Diseases and Pan-American Health Organization have adopted a revised classification of \"dengue\" and \"severe dengue\" &mdash; \"severe dengue\" is applied to patients who show severe plasma leakage (ie, leading to shock or fluid accumulation with respiratory distress), severe hemorrhage (as defined by the treating physician), or severe organ impairment (defined as aspartate transaminase (AST) or ALT &ge;1000, impaired consciousness, or severe involvement of the heart or other organs) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/38\">",
"       38",
"      </a>",
"      ]. The revised classification further divides nonsevere dengue into dengue with or without \"warning signs\" (abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy or restlessness, liver enlargement &gt;2 cm, or increase in hematocrit concurrent with rapid decrease in platelet count). Given the limited experience with this revised classification scheme, its sensitivity and specificity for guiding management of patients in general practice are not known. Therefore, these revised guidelines recommend laboratory confirmation of dengue virus infection when plasma leakage is absent.",
"     </li>",
"     <li>",
"      The WHO Regional Office for South-East Asia (SEARO) adopted a more modest revision of the older dengue classification scheme [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/3\">",
"       3",
"      </a>",
"      ]. The three categories of undifferentiated fever, DF, and DHF were retained, with the addition of a fourth category of expanded dengue syndrome, encompassing those patients who present with any of the unusual features described above in association with dengue virus infection, including those with isolated severe organ dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue virus infection should be considered in the differential diagnosis of a febrile illness in any patient who has resided in or traveled to an appropriate region in the two weeks before the onset of illness. In patients with the features of dengue fever (DF), the differential diagnosis includes: influenza, enteroviral infection, measles, and rubella. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the appropriate epidemiologic settings, malaria, leptospirosis, and typhoid fever must also be considered, and appropriate laboratory testing performed. Analysis of data from over 17,000 ill travelers in the GeoSentinel Surveillance Network found that dengue accounted for 10.4 percent of post-travel systemic febrile illnesses, second only to malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/39\">",
"     39",
"    </a>",
"    ]. Dengue was the most frequently identified cause of systemic febrile illness among travelers returning from Southeast Asia (32 percent), the Caribbean (24 percent), South Central Asia (14 percent), and South America (14 percent), and was only slightly less common than malaria among travelers returning from Central America (12 percent of cases). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who live or who have recently traveled to central and northeast China, Severe Fever with Thrombocytopenia Syndrome (SFTS) should also be considered in the differential diagnosis; this infection is caused by a novel bunyavirus and is associated with fever, leukopenia, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/40\">",
"     40",
"    </a>",
"    ]. Among cases described to date, SFTS has been characterized by prominent gastrointestinal symptoms, including nausea (69 percent of cases), abdominal pain or tenderness (49 percent), vomiting (47 percent), and diarrhea (42 percent). The candidate vector is a tick from the Ixodidae family. Among 171 confirmed cases in a 2011 report, there were 21 deaths (12 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute dengue virus infection is mainly a clinical one. In developing countries, laboratory confirmation is typically not available. In developed countries, laboratory confirmation is usually available only in specialized reference laboratories and is often not sufficiently timely to assist in the management of the illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of dengue fever (DF) or dengue hemorrhagic fever (DHF) with or without shock can be helpful in making a provisional diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of children with febrile illnesses in Thailand reported that some clinical features, such as a positive tourniquet test, leukopenia, thrombocytopenia, and increased serum aspartate transaminase (AST) levels, were more frequent in patients with dengue than in those with other febrile illnesses [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/15\">",
"       15",
"      </a>",
"      ]. However, none of these features of classic DF is sufficiently sensitive or specific to permit a reliable diagnosis.",
"     </li>",
"     <li>",
"      A systematic review of the English language literature from 1990 to 2007 identified 15 studies that evaluated the usefulness of clinical criteria to distinguish dengue from other febrile illnesses among populations living in dengue-endemic areas [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/16\">",
"       16",
"      </a>",
"      ]. Although study methodologies varied widely, and many weaknesses in study design",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reporting were identified, low platelets, white blood cell and neutrophil counts, elevated hepatic transaminases, and the presence of petechiae, were associated with a confirmed diagnosis of dengue across multiple studies.",
"     </li>",
"     <li>",
"      One study applied decision tree classification analysis to clinical, hematological, and virological data from 1200 patients presenting within the first 72 hours of an acute febrile illness [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/41\">",
"       41",
"      </a>",
"      ]. Of these, 364 were dengue reverse transcriptase-polymerase chain reaction (RT-PCR) positive; 173 had DF, 171 had dengue hemorrhagic fever, and 20 had dengue shock syndrome as final diagnoses. The diagnostic algorithm utilized platelet count, WBC, neutrophil and lymphocyte counts, hematocrit, and body temperature, and showed an accuracy of 85 percent for classification of patients with dengue versus non-dengue illnesses from this dataset; the algorithm has not been validated on other patient populations, however.",
"     </li>",
"     <li>",
"      In developing countries, dengue hemorrhagic fever is frequently diagnosed based upon the clinical case definition established by the World Health Organization (WHO) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Dengue hemorrhagic fever'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/3,18\">",
"       3,18",
"      </a>",
"      ]. In regions (and seasons) with a high incidence of DHF, the positive predictive value of the case definition is high. Laboratory tests confirm dengue virus infection in as many as 90 percent of such cases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. However, malaria, leptospirosis, or typhoid fever must be considered in the differential diagnosis of DHF. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When dengue virus infection (DF or DHF) is suspected on clinical grounds, the patient should be treated empirically as appropriate for the symptoms and signs present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of acute dengue virus infection is most frequently accomplished using serology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/18,44\">",
"     18,44",
"    </a>",
"    ]. Tests for detection of viral RNA or NS1 antigen are commercially available and more successful than serology in detecting dengue virus infection in the early stages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/45\">",
"     45",
"    </a>",
"    ]. We recommend the following diagnostic approach to the patient with suspected dengue if laboratory support is available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/18,44\">",
"     18,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute phase serum or plasma sample should be obtained.",
"     </li>",
"     <li>",
"      If the acute phase sample is obtained &ge;3 days after the onset of illness, the IgM immunoassay (MAC-ELISA or equivalent) is the procedure of choice for rapid confirmation of the diagnosis. The potential for a false-negative result remains elevated within the first six days of illness, however. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Serologic testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the acute phase sample is obtained within the first three days after the onset of illness, or if the sample is obtained within the first six days of illness and there is a negative IgM assay result, testing for the presence of the dengue viral RNA or NS1 antigen has the highest diagnostic yield. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Virus detection'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      To confirm a positive IgM result, or if initial testing is negative in a patient with suspected dengue virus infection, a convalescent phase serum sample should be obtained at least 10 to 14 days after the acute phase serum. The acute and convalescent specimens should be analyzed together by a hemagglutination inhibition (HI) or enzyme immunoassay to provide definitive serologic testing for acute dengue virus infection. These tests are not licensed for use in the United States, however, and results do not affect clinical management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion of serologic testing and viral detection methods follows.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used serologic tests for the diagnosis of acute dengue virus infection are the hemagglutination inhibition (HI) assay and IgG or IgM enzyme immunoassays. Complement fixation and neutralizing antibody assays are more technically demanding and are used in specialized laboratories only. Thus far the US Food and Drug Administration (FDA) has approved the IgM capture enzyme linked immunosorbent assay (ELISA) for use in the United States.",
"   </p>",
"   <p>",
"    The HI assay historically has been and remains the gold standard for serologic testing for dengue virus-specific antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/18\">",
"     18",
"    </a>",
"    ]. Analysis of paired acute and convalescent serum samples is essential; a fourfold or greater rise in HI antibody titer between acute and convalescent samples defines acute infection. However, cross-reactivity with other flaviviruses has been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link\">",
"     \"Yellow fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antibody response will depend on whether the patient has primary or secondary dengue virus infection. In primary infection, HI antibodies develop late (after the fifth day of illness) and reach titers of less than 1:1250 in the convalescent phase. By contrast, HI antibodies rise early in secondary infection and reach titers above 1:1250 (often 1:10,240 or higher) in the convalescent phase.",
"   </p>",
"   <p>",
"    Immunoassays for the detection of dengue virus-specific IgG antibodies have demonstrated sensitivity and specificity of approximately 99 percent and 96 percent, respectively, compared with the HI assay [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/46\">",
"     46",
"    </a>",
"    ]. As with the HI assay, diagnosis of acute dengue virus infection using the IgG ELISA requires testing of paired acute and convalescent serum samples, showing a greater than fourfold rise in antibody titer.",
"   </p>",
"   <p>",
"    One assay that can use a single blood specimen for diagnosis of dengue infection is the IgM antibody capture ELISA or MAC-ELISA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/44\">",
"     44",
"    </a>",
"    ]. Dengue virus-specific IgM antibodies are typically detected by the MAC-ELISA by about the sixth day of illness and persist for 30 to 90 days. If positive, this test can assist in rapid diagnosis of the patient with dengue infection. However, the sensitivity and specificity of this assay is much lower than the HI assay. In one study of Thai children with predominantly secondary dengue virus infections, only 29 percent of subjects had a positive result in the MAC-ELISA by the time of defervescence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/47\">",
"     47",
"    </a>",
"    ]. Factors that reduce the sensitivity or specificity of the MAC-ELISA include occasional blunting of the IgM antibody response in secondary dengue virus infections and the potential for positive results to reflect recent rather than acute dengue virus infection.",
"   </p>",
"   <p>",
"    The development of rapid diagnostic tests using immunochromatographic or immunoblot technologies has provided a mechanism for bedside serological testing. However, in one report, diagnostic accuracy fell below the manufacturer's claims; when eight of these available assays were tested in the field, only two had sensitivities of &gt;50 percent, and of these, one assay also had low specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Virus detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of dengue virus or detection of dengue viral RNA or protein in an acute phase serum or tissue specimen provides the most definitive confirmation of infection. However, the importance of specimen timing and quality and the technical demands of these assays limits their clinical applications. As mentioned above, when laboratory confirmation of illness is obtained, it is typically with serology.",
"   </p>",
"   <p>",
"    In the United States, most diagnostic laboratory testing for dengue virus infection has been performed by the Dengue Branch of the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/44\">",
"     44",
"    </a>",
"    ]. Serum samples must be submitted with appropriate clinical and epidemiologic information through state health department laboratories. A real-time RT-PCR assay kit, developed by the CDC was approved by the FDA in 2012 for diagnostic use in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/49\">",
"     49",
"    </a>",
"    ]. In both prospective and retrospective testing, the sensitivity and specificity of the test were &ge;98 percent compared to a reference method [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/50\">",
"     50",
"    </a>",
"    ]. The CDC DENV-1-4 Real Time RT PCR Assay was designed to be performed on equipment already in use in many clinical and public health laboratories in the United States, and should expand the availability of early diagnostic testing.",
"   </p>",
"   <p>",
"    Virus isolation is generally performed only for epidemiologic or research purposes. Serum and plasma are the preferred specimens for virus isolation, although virus can occasionally be isolated from liver tissues after clearance of virus from the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/51\">",
"     51",
"    </a>",
"    ]. Regardless of the specific method used, optimal detection is achieved when specimens are obtained early after the onset of symptoms, during the febrile period. In one study of children in Thailand, dengue viruses could be isolated from all plasma samples obtained at least two days before defervescence but from no samples obtained two or more days after fevers resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/47\">",
"     47",
"    </a>",
"    ]. Virus isolation typically requires one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT-PCR has comparable sensitivity to viral isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Although technically demanding and not widely available, RT-PCR is the only method that can detect virus within a clinically meaningful time frame (one to two days) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dengue viral proteins can be detected in tissue samples using immunohistochemical staining [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/58\">",
"     58",
"    </a>",
"    ]. Liver tissues appear to have the highest yield. However, since liver biopsy is rarely indicated in patients with suspected dengue virus infection, this method is generally only used for postmortem diagnosis.",
"   </p>",
"   <p>",
"    The dengue viral nonstructural protein 1 (NS1) can be detected in plasma, especially during the first five to six days of illness. In one study, high levels early in infection were associated with DHF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/59\">",
"     59",
"    </a>",
"    ]. Two assays have become commercially available outside the United States, although neither provides a quantitative measurement of soluble NS1 protein levels. The sensitivity of these assays for diagnosis of acute dengue infection at the time of hospital admission is 50 to 70 percent, with specificity &gt;95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/27/16818?source=see_link\">",
"       \"Patient information: Dengue fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of dengue range from self-limited dengue fever to dengue hemorrhagic fever with shock syndrome, which carries a significant mortality rate. The risk of severe disease is much higher in sequential rather than primary dengue infection. There is also an increasing recognition of atypical syndromes associated with acute dengue virus infection (&ldquo;expanded dengue syndrome&rdquo;), some of which can be severe. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic dengue fever is an acute febrile illness accompanied by headache, retroorbital pain, and marked muscle and joint pains, which evoked the term \"break-bone fever\" [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18985/abstract/10\">",
"       10",
"      </a>",
"      ]. Fever typically lasts for five to seven days. Hemorrhagic manifestations and thrombocytopenia can also occur in patients with dengue fever. Physical examination is nonspecific, but may include a macular or maculopapular rash in approximately 50 percent of cases. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dengue fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dengue hemorrhagic fever is the most serious manifestation of dengue virus infection and can be associated with shock. The four cardinal features of dengue hemorrhagic fever include increased vascular permeability, fever, hemorrhage, and marked thrombocytopenia (100,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or lower). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dengue hemorrhagic fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma leakage is the most specific and life-threatening feature of dengue hemorrhagic fever and usually occurs over a period of 24 to 48 hours, typically coincident with defervescence. Severe plasma leakage can occur in patients with minimal hemorrhagic manifestations. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dengue hemorrhagic fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemorrhagic manifestations of dengue virus infection can range from spontaneous petechiae to profuse bleeding. Severe bleeding sometimes occurs in the absence of plasma leakage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dengue fever'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Dengue hemorrhagic fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute dengue virus infection is based mainly on clinical signs and symptoms in endemic countries. In settings where serologic assays are available, we favor use of an acute phase serum sample for use in an IgM immunoassay (MAC-ELISA or equivalent) as the laboratory test of choice. If the IgM immunoassay is negative and the serum was obtained within the first six days after onset of illness, we favor testing the sample for dengue viral NS1 antigen by ELISA. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the clinical suspicion of dengue virus infection is high and the assay results on the acute phase sample are negative, we favor testing paired acute and convalescent sera for antibodies to dengue virus by hemagglutination inhibition assay or IgG ELISA. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/1\">",
"      Kroeger A, Nathan M, Hombach J, World Health Organization TDR Reference Group on Dengue. Dengue. Nat Rev Microbiol 2004; 2:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/2\">",
"      Teixeira MG, Barreto ML. Diagnosis and management of dengue. BMJ 2009; 339:b4338.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Regional Office for Southeast Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Revised and expanded version. SEARO Technical Publication Series, New Delhi, India 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/4\">",
"      Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med 2012; 366:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/5\">",
"      Deen JL, Harris E, Wills B, et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 2006; 368:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/6\">",
"      SABIN AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/7\">",
"      Sharp TW, Wallace MR, Hayes CG, et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg 1995; 53:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/8\">",
"      Endy TP, Chunsuttiwat S, Nisalak A, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/9\">",
"      Shirtcliffe P, Cameron E, Nicholson KG, Wiselka MJ. Don't forget dengue! Clinical features of dengue fever in returning travellers. J R Coll Physicians Lond 1998; 32:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/10\">",
"      Rigau-P&eacute;rez JG. The early use of break-bone fever (Quebranta huesos, 1771) and dengue (1801) in Spanish. Am J Trop Med Hyg 1998; 59:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/11\">",
"      Schwartz E, Mendelson E, Sidi Y. Dengue fever among travelers. Am J Med 1996; 101:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/12\">",
"      Cobra C, Rigau-P&eacute;rez JG, Kuno G, Vorndam V. Symptoms of dengue fever in relation to host immunologic response and virus serotype, Puerto Rico, 1990-1991. Am J Epidemiol 1995; 142:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/13\">",
"      Trofa AF, DeFraites RF, Smoak BL, et al. Dengue fever in US military personnel in Haiti. JAMA 1997; 277:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/14\">",
"      Srikiatkhachorn A, Gibbons RV, Green S, et al. Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005. Clin Infect Dis 2010; 50:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/15\">",
"      Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/16\">",
"      Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop Med Int Health 2008; 13:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/17\">",
"      Halstead SB. Dengue. Lancet 2007; 370:1644.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Dengue hemorrhagic fever: diagnosis, treatment, prevention, and control. 2nd ed. Geneva: World Health Organization, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/19\">",
"      Phuong CX, Nhan NT, Kneen R, et al. Clinical diagnosis and assessment of severity of confirmed dengue infections in Vietnamese children: is the world health organization classification system helpful? Am J Trop Med Hyg 2004; 70:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/20\">",
"      Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 1993; 92:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/21\">",
"      D&iacute;az A, Kour&iacute; G, Guzm&aacute;n MG, et al. Description of the clinical picture of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) in adults. Bull Pan Am Health Organ 1988; 22:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/22\">",
"      Guzm&aacute;n MG, Kour&iacute; G, Mart&iacute;nez E, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 1987; 21:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/23\">",
"      Khor BS, Liu JW, Lee IK, Yang KD. Dengue hemorrhagic fever patients with acute abdomen: clinical experience of 14 cases. Am J Trop Med Hyg 2006; 74:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/24\">",
"      Rigau-P&eacute;rez JG, Laufer MK. Dengue-related deaths in Puerto Rico, 1992-1996: diagnosis and clinical alarm signals. Clin Infect Dis 2006; 42:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/25\">",
"      Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, et al. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J 2007; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/26\">",
"      Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005; 353:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/27\">",
"      Cao XT, Ngo TN, Wills B, et al. Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Viet Nam. Trop Med Int Health 2002; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/28\">",
"      Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with unusual manifestations. Southeast Asian J Trop Med Public Health 1987; 18:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/29\">",
"      Chhour YM, Ruble G, Hong R, et al. Hospital-based diagnosis of hemorrhagic fever, encephalitis, and hepatitis in Cambodian children. Emerg Infect Dis 2002; 8:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/30\">",
"      Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet 2000; 355:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/31\">",
"      Patey O, Ollivaud L, Breuil J, Lafaix C. Unusual neurologic manifestations occurring during dengue fever infection. Am J Trop Med Hyg 1993; 48:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/32\">",
"      Misra UK, Kalita J, Syam UK, Dhole TN. Neurological manifestations of dengue virus infection. J Neurol Sci 2006; 244:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/33\">",
"      Ara&uacute;jo FM, Ara&uacute;jo MS, Nogueira RM, et al. Central nervous system involvement in dengue: a study in fatal cases from a dengue endemic area. Neurology 2012; 78:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/34\">",
"      Chan DP, Teoh SC, Tan CS, et al. Ophthalmic complications of dengue. Emerg Infect Dis 2006; 12:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/35\">",
"      Wilder-Smith A, Tambyah PA. Severe dengue virus infection in travelers. J Infect Dis 2007; 195:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/36\">",
"      Anderson KB, Chunsuttiwat S, Nisalak A, et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007; 369:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/37\">",
"      Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis 2007; 195:1089.",
"     </a>",
"    </li>",
"    <li>",
"     Anonymous. Dengue: guidelines for diagnosis, treatment, prevention and control- new edition. World Health Organization, Geneva 2009, p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/39\">",
"      Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/40\">",
"      Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011; 364:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/41\">",
"      Tanner L, Schreiber M, Low JG, et al. Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl Trop Dis 2008; 2:e196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/42\">",
"      Guzman MG, Kouri GP, Bravo J, et al. Dengue haemorrhagic fever in Cuba. II. Clinical investigations. Trans R Soc Trop Med Hyg 1984; 78:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/43\">",
"      Kalayanarooj S, Chansiriwongs V, Nimmannitya S. Dengue patients at the Children&rsquo;s Hospital, Bangkok: 1995-1999 review. Dengue Bulletin 2002; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/44\">",
"      Rigau-P&eacute;rez JG, Gubler DJ, Vorndam AV, Clark GG. Dengue surveillance--United States, 1986-1992. MMWR CDC Surveill Summ 1994; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/45\">",
"      Blacksell SD, Mammen MP Jr, Thongpaseuth S, et al. Evaluation of the Panbio dengue virus nonstructural 1 antigen detection and immunoglobulin M antibody enzyme-linked immunosorbent assays for the diagnosis of acute dengue infections in Laos. Diagn Microbiol Infect Dis 2008; 60:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/46\">",
"      McBride WJ, Mullner H, LaBrooy JT, Wronski I. The 1993 dengue 2 epidemic in North Queensland: a serosurvey and comparison of hemagglutination inhibition with an ELISA. Am J Trop Med Hyg 1998; 59:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/47\">",
"      Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/48\">",
"      Blacksell SD, Newton PN, Bell D, et al. The comparative accuracy of 8 commercial rapid immunochromatographic assays for the diagnosis of acute dengue virus infection. Clin Infect Dis 2006; 42:1127.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/media/releases/2012/p0620_dengue_test.html (Accessed on July 17, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC DENV-1-4 Real-Time RT-PCR Assay. Package insert. file://www.cdc.gov/dengue/resources/rt_pcr/CDCPackageInsert.pdf (Accessed on November 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/51\">",
"      Rosen L, Khin MM, U T. Recovery of virus from the liver of children with fatal dengue: reflections on the pathogenesis of the disease and its possible analogy with that of yellow fever. Res Virol 1989; 140:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/52\">",
"      Rosen L. The use of Toxorhynchites mosquitoes to detect and propagate dengue and other arboviruses. Am J Trop Med Hyg 1981; 30:177.",
"     </a>",
"    </li>",
"    <li>",
"     Deubel V. The contribution of molecular techniques to the diagnosis of dengue infection. In: Dengue and Dengue Hemorrhagic Fever, Gubler DJ, Kuno G (Eds), CAB International, CAB International 1997. p.335.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/54\">",
"      Sudiro TM, Ishiko H, Green S, et al. Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers. Am J Trop Med Hyg 1997; 56:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/55\">",
"      Chien LJ, Liao TL, Shu PY, et al. Development of real-time reverse transcriptase PCR assays to detect and serotype dengue viruses. J Clin Microbiol 2006; 44:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/56\">",
"      Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 2005; 43:4977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/57\">",
"      de Oliveira Poersch C, Pavoni DP, Queiroz MH, et al. Dengue virus infections: comparison of methods for diagnosing the acute disease. J Clin Virol 2005; 32:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/58\">",
"      Hall WC, Crowell TP, Watts DM, et al. Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg 1991; 45:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/59\">",
"      Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002; 186:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/60\">",
"      Guzman MG, Jaenisch T, Gaczkowski R, et al. Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 2010; 4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18985/abstract/61\">",
"      Blacksell SD, Jarman RG, Gibbons RV, et al. Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin Vaccine Immunol 2012; 19:804.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3025 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18985=[""].join("\n");
var outline_f18_34_18985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asymptomatic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dengue fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Classic dengue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hemorrhagic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dengue hemorrhagic fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Plasma leakage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hemorrhagic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Expanded dengue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLASSIFICATION CONTROVERSIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Virus detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=related_link\">",
"      Pathogenesis of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/27/16818?source=related_link\">",
"      Patient information: Dengue fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=related_link\">",
"      Prevention and treatment of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_34_18986="Overview of the treatment of hyponatremia";
var content_f18_34_18986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of hyponatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18986/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18986/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/34/18986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/34/18986/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/34/18986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia represents a relative excess of water in relation to sodium. It can be induced by a marked increase in water intake (primary polydipsia) or, in the great majority of cases, by impaired water excretion resulting from advanced renal failure or from persistent release of antidiuretic hormone (ADH) induced by reduced effective arterial blood volume, the syndrome of inappropriate ADH secretion (SIADH), thiazide diuretics, adrenal insufficiency, or hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with hyponatremia have chronic (ie, gradual onset) hyponatremia, a serum sodium concentration above 120",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and appear asymptomatic, although subtle neurologic abnormalities may be present when the serum sodium is between 120 and 130",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Necessity for therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initial treatment in such patients typically consists of slow correction of the hyponatremia via fluid restriction or, if volume depletion is present, the administration of isotonic saline (or oral salt tablets) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Vasopressin receptor antagonists also may be helpful. Among patients with SIADH, isotonic saline may worsen the hyponatremia. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'SIADH'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    More aggressive therapy is indicated in patients who have symptomatic or severe hyponatremia (serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    In this setting, initial therapy usually consists of hypertonic saline with or without vasopressin receptor antagonists.",
"   </p>",
"   <p>",
"    The following issues are reviewed in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The optimal method of raising the serum sodium concentration, which varies with the cause of hyponatremia",
"     </li>",
"     <li>",
"      Estimation of the sodium deficit if sodium is to be given",
"     </li>",
"     <li>",
"      The optimal rate of correction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of correction is important because overly rapid correction of severe hyponatremia can lead to a severe and sometimes irreversible neurologic disorder called osmotic demyelination syndrome. One group that is probably not at risk for this complication is patients with hyperacute hyponatremia that develops over a few hours due to a marked increase in water intake as may be seen in marathon runners, psychotic patients, and users of ecstasy. Issues related to osmotic demyelination syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODS OF RAISING THE SERUM SODIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum sodium concentration can be raised in hyponatremic patients by one or more of the following approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treat the underlying disease, if possible.",
"     </li>",
"     <li>",
"      Fluid restriction.",
"     </li>",
"     <li>",
"      Oral or intravenous sodium chloride in patients with true volume depletion. Sodium chloride administration is also effective in patients the syndrome of inappropriate antidiuretic hormone secretion (SIADH) using either oral salt tablets or hypertonic saline. In contrast, isotonic saline is often not effective and may worsen the hyponatremia in SIADH. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'SIADH'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administration of a vasopressin receptor antagonist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These approaches will be discussed in detail in the following sections. In addition, initial therapy with hypertonic saline is warranted in patients with neurologic symptoms attributable to hyponatremia, particularly if severe. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Choice of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treat the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the specific therapies described below that are aimed at correcting the hyponatremia, therapy should also be directed at the underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several circumstances in which the underlying disease can be corrected quickly, possibly leading to overly rapid correction of the hyponatremia (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Avoid overly rapid correction'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of saline to patients with true volume depletion. In this setting, restoration of euvolemia will suppress the release of ADH (which has a half-life of only 15 to 20 minutes), thereby allowing rapid excretion of the excess water. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'True volume depletion'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The administration of glucocorticoids to patients with adrenal insufficiency, which will directly suppress the release of ADH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link\">",
"       \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Relatively rapid reversal of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). This can occur with self-limited disease (eg, nausea, pain, surgery) and with cessation of therapy with certain drugs that cause SIADH such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      and selective serotonin reuptake inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are a number of other causes of hyponatremia that can be corrected in which the serum sodium rises more slowly. This is most often seen with thyroid hormone replacement in patients with hypothyroidism and by gradually reversing the cause of SIADH by, for example, the treatment of tuberculosis or meningitis or the cessation of long-acting drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H88313973#H88313973\">",
"     \"Causes of hyponatremia\", section on 'Hypothyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid restriction to below the level of urine output is indicated for the treatment of symptomatic or severe hyponatremia in edematous states (such as heart failure and cirrhosis), the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and advanced renal failure. Restriction to 50 to 60 percent of daily fluid requirements may be required to achieve the goal of inducing negative water balance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, fluid intake should be less than 800",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"    In patients with a highly concentrated urine (eg, 500",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    or higher), fluid restriction alone may be insufficient to correct hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Fluid restriction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H10#H10\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Fluid restriction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Fluid restriction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid restriction is also warranted in hyponatremic patients with primary polydipsia in whom increased fluid intake is the primary problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of hyponatremia\", section on 'Primary polydipsia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sodium chloride administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium chloride, usually as isotonic saline or increased dietary salt, is given to hyponatremic patients with true volume depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adrenal insufficiency and to some patients with SIADH. Salt administration is generally contraindicated for chronic therapy in edematous patients (eg, heart failure, cirrhosis, renal failure) since it will lead to exacerbation of the edema.",
"   </p>",
"   <p>",
"    Administration of hypertonic saline is primarily limited to patients with symptomatic or severe hyponatremia or, occasionally, to patients with SIADH and a highly concentrated urine. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Severe symptoms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'SIADH'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The degree to which isotonic saline will raise the serum sodium concentration in hyponatremic patients varies with the cause of the hyponatremia. As illustrated by the following discussion, the response to isotonic saline differs in volume depletion and SIADH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     True volume depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In states of true volume depletion (eg, diarrhea, vomiting, diuretic therapy), the administered sodium and water will initially be retained. In this setting, isotonic saline corrects the hyponatremia by two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It slowly raises the serum sodium by approximately 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for every liter of fluid infused since isotonic saline has a higher sodium concentration (154",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      than the hyponatremic plasma.",
"     </li>",
"     <li>",
"      By correcting the hypovolemia, it removes the stimulus to ADH release, thereby allowing the excess water to be excreted in a dilute urine. At this time, the serum sodium concentration may return rapidly toward normal; in selected patients, overly rapid correction of hyponatremia can lead to a severe neurologic disorder called osmotic demyelination [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. The management of such patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168163314\">",
"    <span class=\"h4\">",
"     Equation to estimate efficacy of initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which one liter of a given solution will initially raise the serum sodium concentration (SNa) in a hyponatremic patient can be estimated from the Adrogu&eacute;-Madias formula [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/4\">",
"     4",
"    </a>",
"    ], the clinical utility of which is discussed below (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Estimation of the sodium deficit'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    &nbsp;Increase in SNa &nbsp;= &nbsp;(Infusate [Na] &ndash; SNa) &nbsp;&divide; &nbsp;(TBW + 1)",
"   </p>",
"   <p>",
"    where TBW is the estimated total body water (lean body weight times 0.5 for women, 0.6 for men). The TBW rather than extracellular fluid volume is used in this equation since, although the administered sodium will stay in the extracellular space, water moves from the intracellular to extracellular space in response to the administered sodium to equalize the osmolality of the two fluid compartments.",
"   </p>",
"   <p>",
"    Potassium added to the solution should be included in the formula (ie, \"Infusate [Na + K]\" rather than \"Infusate [Na]\") since potassium is as osmotically active as sodium and will therefore contribute to the elevation in serum sodium. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Effect of potassium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example of how this formula can be used to estimate the effect of initial therapy, suppose that one liter of isotonic saline (containing 154",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of sodium) is given to a 60 kg women with a serum sodium concentration of 110",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and an estimated TBW of 30 L (50 percent of lean body weight). The saline solution should initially raise the serum sodium by approximately 1.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to 111.4",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Increase in SNa &nbsp;= &nbsp;(154 &ndash; 110) &nbsp;&divide; &nbsp;31 &nbsp;= &nbsp;1.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    A major limitation of this formula in patients with true volume depletion is that it does not take into account the increase in water excretion that will occur when euvolemia is restored and ADH secretion is appropriately suppressed by the hyponatremia. In addition, the formula",
"    <strong>",
"     cannot",
"    </strong>",
"    be used to predict the increase in serum sodium in patients with SIADH since the administered sodium will be excreted in the urine and some of the water retained, possibly worsening the hyponatremia. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'SIADH'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A more complete understanding of the effect on serum sodium and total body water is provided by the following approach. Since the osmolality in the cells (where potassium is the primary solute) is the same as that in the extracellular fluid, the effect of the serum sodium concentration (SNa) is distributed through the total body water (TBW). The term exchangeable cation in the following equations refers to the body content of osmotically active sodium and potassium ions, not sodium and potassium present in bone.",
"   </p>",
"   <p>",
"    Thus, in this 60 kg woman with a serum sodium of 110",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Total body exchangeable cation &nbsp;= &nbsp;TBW &nbsp;x &nbsp;SNa &nbsp;= &nbsp;30 &nbsp;x &nbsp;110 &nbsp;= 3300 meq",
"   </p>",
"   <p>",
"    Assuming that the extracellular fluid (ECF) is approximately 33 percent (10 L) and the intracellular fluid is approximately 67 percent (20 L) of the total body water [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Extracellular exchangeable cation &nbsp;= &nbsp;10 &nbsp;x &nbsp;110 &nbsp;= &nbsp;1100 meq",
"   </p>",
"   <p>",
"    The administration and retention of 1000 mL of isotonic saline containing 154 meq of sodium will raise the TBW to 31 L, the total body exchangeable cation to 3454 meq and since all of the sodium chloride will stay in the ECF, the extracellular exchangeable cation to 1254 meq. Thus:",
"   </p>",
"   <p>",
"    &nbsp;New SNa &nbsp;= &nbsp;Total exchangeable cation &divide; &nbsp;TBW &nbsp;= &nbsp;3454 &nbsp;&divide; &nbsp;31 &nbsp;= &nbsp;111.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    New ECF volume &nbsp;= &nbsp;Total ECF exchangeable cation &nbsp;&divide; &nbsp;SNa &nbsp;= &nbsp;1254 &nbsp;&divide; &nbsp;111.4 &nbsp;= &nbsp;11.3 L",
"   </p>",
"   <p>",
"    The ECF volume has increased by 1.3 L. This is more than the 1 L of saline given because the rise in serum sodium concentration and plasma osmolality results in osmotic water movement from the cells into the extracellular fluid.",
"   </p>",
"   <p>",
"    These calculations illustrate the relatively limited direct effect of isotonic saline to correct hyponatremia. In the hypovolemic patient, the much more important effect is restoration of euvolemia with subsequent suppression of ADH release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to hypovolemia, the response to administered isotonic saline is different in a hyponatremic patient with SIADH. Assuming the patient is euvolemic, the administered sodium is excreted in the urine because the response to aldosterone and atrial natriuretic peptide are normal. However, the water is retained because of the persistent action of ADH. Thus, when one liter of isotonic saline is administered to a patient with SIADH, the sodium is excreted in the urine while some of the water is retained, worsening the hyponatremia.",
"   </p>",
"   <p>",
"    A few simple calculations can illustrate this point. Suppose a patient with SIADH and hyponatremia has a high, relatively fixed urine osmolality and a urine cation concentration (urine [Na] + urine [K]) of 308",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which is twice the cation concentration of isotonic saline. If 1000 mL of isotonic saline is given (containing 154 meq of sodium), all of the NaCl will be excreted (because sodium handling is intact) but in only 500 mL of water (154 meq of urinary sodium in 500 mL equals 308",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    The retention of one-half of the administered water will lead to a further reduction in the serum sodium concentration even though the serum sodium concentration will temporarily increase because the isotonic saline is hypertonic to the patient.",
"   </p>",
"   <p>",
"    Using the hypothetical 60 kg woman with a serum sodium of 110",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and the equations that were presented in the preceding section (see",
"    <a class=\"local\" href=\"#H168163314\">",
"     'Equation to estimate efficacy of initial therapy'",
"    </a>",
"    above), the effect of 500 mL of retained will be:",
"   </p>",
"   <p>",
"    &nbsp;New SNa &nbsp;= &nbsp;Total exchangeable cation &nbsp;&divide; &nbsp;total body water (TBW)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;= &nbsp;3300 meq (same as baseline) &nbsp;&divide; &nbsp;30.5 L (500 mL increase)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;= &nbsp;108",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    Support for possible harm from isotonic saline was provided in a report of 22 women who underwent uncomplicated gynecologic surgery and had been treated with modest volumes of only isotonic saline or near-isotonic Ringer's lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/9\">",
"     9",
"    </a>",
"    ]. At 24 hours after induction of anesthesia, the serum sodium fell by a mean of 4.2",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Fatalities from severe hyponatremia have been reported following the administration of large volumes of isotonic fluid after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, hypertonic saline contains 513 meq of sodium per liter. If 1000 mL of this solution is given, all of the NaCl will again be excreted but now in a larger volume of urine. If, as in the above example, the patient with SIADH has a urine cation concentration of 308",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the 513 meq of administered sodium is excreted in 1665 mL of urine (513 &divide; 308",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    Thus, after the administration of hypertonic saline, there will be an initial large rise in the serum sodium concentration followed by reduction toward baseline after the administered sodium has been excreted. At this time, the rise in the serum sodium is entirely due to the net loss of 665 mL of water:",
"   </p>",
"   <p>",
"    &nbsp;New SNa &nbsp;= Total exchangeable cations &nbsp;&divide; &nbsp;TBW",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;= &nbsp;3300 (same as baseline) &nbsp;&divide; &nbsp;29.3 (665 mL loss) &nbsp;= &nbsp;113",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    Treatment of SIADH begins with fluid restriction. The effectiveness of fluid restriction alone can be predicted by the urine to serum electrolyte ratio (the concentration of the urine cations, sodium and potassium, to the serum sodium concentration) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/10\">",
"     10",
"    </a>",
"    ]. A ratio less than 0.5 suggests that the serum sodium concentration will rise with fluid restriction, while a ratio greater than 1 indicates that it will not. Similarly, if fluid must be given or the serum sodium concentration must be raised quickly because of symptomatic hyponatremia, the cation concentration of the administered fluid must exceed the cation concentration of the urine. Isotonic saline has a limited role in correction of the hyponatremia in SIADH, and hypertonic saline must be given when an urgent increase in serum sodium is required. Whenever this is done, careful monitoring of the serum sodium is essential to prevent overly rapid correction. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Rate of correction'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Concurrent use of a loop diuretic may be beneficial in patients with SIADH who have a high urine to serum electrolyte ratio. By inhibiting sodium chloride reabsorption in the thick ascending limb of the loop of Henle,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    interferes with the countercurrent mechanism and induces a state of ADH resistance, resulting in the excretion of a less concentrated urine and increased water loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Salt plus a loop diuretic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic therapy of SIADH is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect of potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium is as osmotically active as sodium. As a result, giving potassium (usually for concurrent hypokalemia) can raise the serum sodium concentration and osmolality in hyponatremic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/7,11-14\">",
"     7,11-14",
"    </a>",
"    ]. Since most of the excess potassium enters the cells, electroneutrality is maintained in one of three ways, each of which will raise the serum sodium concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracellular sodium moves into the extracellular fluid.",
"     </li>",
"     <li>",
"      Extracellular chloride moves into the cells with potassium; the increase in cell osmolality promotes free water entry into the cells.",
"     </li>",
"     <li>",
"      Intracellular hydrogen moves into the extracellular fluid. These hydrogen ions are buffered by extracellular bicarbonate and to a much lesser degree plasma proteins. This buffering renders the hydrogen ions osmotically inactive; the ensuing fall in extracellular osmolality leads to water movement into the cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect is that concurrent administration of potassium must be taken into account when estimating the sodium deficit and anticipating the rate of correction of the hyponatremia. This relationship becomes clinically important in the patient with severe diuretic or vomiting-induced hyponatremia who is also hypokalemic.",
"   </p>",
"   <p>",
"    Suppose, for example, that a patient with hyponatremia has a serum potassium concentration of 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and that it is decided to give 400 meq of potassium during the first day. If the patient is a 70 kg man, the total body water will be approximately 40 liters (60 percent of body weight). Using the equations presented above, the administered potassium will raise the serum sodium concentration by about 10",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which exceeds the upper limit for the rate of safe correction. Thus, giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    alone will correct",
"    <strong>",
"     both",
"    </strong>",
"    the hyponatremia and the hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Giving additional sodium may lead to an overly rapid elevation in the serum sodium concentration and potentially cause the osmotic demyelination syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Rate of correction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, when calculating the impact of a particular regimen on the serum sodium concentration, one must consider the sodium plus potassium concentration of the solution, not simply the sodium concentration. Similar considerations apply to calculating the impact of fluid losses induced by vomiting, diarrhea, or diuretic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative or possible addition to fluid restriction and sodium chloride administration in patients with hyponatremia is the use of an ADH receptor antagonist. There are multiple receptors for vasopressin (ADH): the V1a, V1b, and V2 receptors. The V2 receptors primarily mediate the antidiuretic response, while V1a and V1b receptors principally cause vasoconstriction and mediate adrenocorticotropic hormone (ACTH) release, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasopressin receptor antagonists produce a selective water diuresis (also called aquaresis) without affecting sodium and potassium excretion. The ensuing loss of free water will tend to correct the hyponatremia. However, thirst increases significantly with these agents, which may limit the rise in serum sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/5,15\">",
"     5,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some oral formulations, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , mozavaptan, satavaptan, and lixivaptan, are selective for the V2 receptor, while an intravenous agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    , blocks both the V2 and V1a receptors. Only tolvaptan and conivaptan are currently available in the United States.",
"   </p>",
"   <p>",
"    With respect to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     conivaptan",
"    </a>",
"    , there are concerns that the concurrent V1a receptor blockade might lower the blood pressure and increase the risk of variceal bleeding in patients with cirrhosis since vasopressin is used to treat active bleeding in such patients (a V1a effect). There is also a concern that V1a receptor blockade might worsen renal function in patients with cirrhosis since terlipressin, a V1a receptor agonist, has been used to treat hepatorenal syndrome.",
"   </p>",
"   <p>",
"    The studies that have evaluated the use of vasopressin receptor antagonists in the different settings in which hyponatremia occurs are presented elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SIADH (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Heart failure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"       \"Hyponatremia in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=see_link&amp;anchor=H12#H12\">",
"       \"Possibly effective emerging therapies for heart failure\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cirrhosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H12#H12\">",
"       \"Hyponatremia in patients with cirrhosis\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H5672085#H5672085\">",
"       \"Hepatorenal syndrome\", section on 'Terlipressin plus albumin where available'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An example of the potential efficacy of these drugs was provided in a combined report of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    in two randomized, double-blind, placebo-controlled multicenter trials (SALT-1 and SALT-2) in 448 patients with hyponatremia (mean serum sodium 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    caused by SIADH, heart failure, or cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/15\">",
"     15",
"    </a>",
"    ]. Compared with placebo, tolvaptan significantly increased the serum sodium concentration at day 4 (134 to 135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    versus 130",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and day 30 (136 versus 131",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    Among patients with a serum sodium below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline, tolvaptan was also associated with a statistically significant improvement in mental status scores. However, the difference was usually not clinically significant and long-term efficacy is uncertain since the duration of follow-up was only 30 days.",
"   </p>",
"   <p>",
"    In an open-label extension (called SALTWATER), 111 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    for a mean follow-up of almost two years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/16\">",
"     16",
"    </a>",
"    ]. The mean serum sodium was maintained at more than 135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    compared to 131",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline. The responses were similar in SIADH and heart failure, and more modest in cirrhosis. The main adverse effects were abnormally frequent urination, thirst, dry mouth, fatigue, polyuria, and polydipsia. Adverse effects that were possibly or probably related to tolvaptan led to discontinuation of therapy in six patients (5.4 percent).",
"   </p>",
"   <p>",
"    Vasopressin receptor antagonists should",
"    <strong>",
"     not",
"    </strong>",
"    be used in hyponatremic patients who are volume depleted in whom volume repletion with saline is the primary therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'True volume depletion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major potential adverse effects associated with oral V2 receptor antagonists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concerns about the safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      were raised by a multicenter trial (TEMPO 3:4) that examined its effect on the progression of kidney disease in polycystic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. A greater than 2.5-fold increase in liver enzymes was more common among patients who received tolvaptan compared with placebo. Based upon these data, the United States Food and Drug Administration (FDA) issued a safety warning regarding the use of tolvaptan [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/19\">",
"       19",
"      </a>",
"      ]. The FDA recommends that liver function tests be promptly performed among patients who report symptoms that suggest liver injury, including fatigue, anorexia, right upper quadrant discomfort, dark urine, or jaundice. In addition, we suggest that liver function tests be measured three to four months after initiating therapy and then again at six-month intervals. If liver injury is suspected, tolvaptan should be discontinued and not reinitiated unless the cause for liver injury is established to be unrelated. The results of the TEMPO 3:4 trial are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H19#H19\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased thirst, which may limit the rise in serum sodium [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overly rapid correction of the hyponatremia, which can lead to irreversible neurologic injury. In the SALT trials, 1.8 percent of patients exceeded the study goal of limiting daily correction to 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/15\">",
"       15",
"      </a>",
"      ]. However, we now recommend that the serum sodium be raised by no more than 8",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      not 12",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      in any 24-hour period. Thus, it is almost certain that more than 1.8 percent of treated patients exceeded the currently recommended rate of corJrection. Because of this risk, hospitalization is required for the initiation or reinitiation of therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Avoid overly rapid correction'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another limiting factor is the prohibitive",
"    <strong>",
"     cost",
"    </strong>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    , which is as high as $300 per tablet in some areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ESTIMATION OF THE SODIUM DEFICIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with true volume depletion and some with SIADH require saline administration to raise the serum sodium. Isotonic saline is typically sufficient in true volume depletion but ineffective in SIADH where, if saline is given, a hypertonic solution is typically required. The mechanisms responsible for these conclusions are described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Sodium chloride administration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Formulas are available to estimate both the sodium deficit and the direct effect of a given fluid (eg, hypertonic saline) on the serum sodium (SNa) concentration. The sodium deficit can be estimated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp; Sodium deficit &nbsp;= &nbsp;Total body water (TBW) &nbsp;x &nbsp;(desired SNa &ndash; actual SNa)",
"   </p>",
"   <p>",
"    Although sodium itself is restricted to the extracellular fluid, increases in the serum sodium concentration lead to water movement out of cells to equalize extracellular and intracellular osmolality. Thus, the effect of sodium is reflected throughout the TBW. TBW is estimated as lean body weight times 0.5 for women and 0.6 for men.",
"   </p>",
"   <p>",
"    The direct effect of one liter of a given solution can be estimated from the following widely used formula (the Adrogu&eacute;-Madias formula) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/4\">",
"     4",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H168163314\">",
"     'Equation to estimate efficacy of initial therapy'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    &nbsp; Increase in SNa &nbsp;= &nbsp;(Infusate [Na] &ndash; SNa) &nbsp;&divide; &nbsp;(TBW + 1)",
"   </p>",
"   <p>",
"    However, these formulas have a number of limitations and often do not accurately predict the magnitude of change in serum sodium. When hypertonic saline is given, the increase in serum sodium is often greater than that predicted by the formula [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As an example, in a series of 62 patients with a baseline serum sodium of 112",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    who were treated with hypertonic saline, 74 percent had a rise in serum sodium greater than expected from the above formula. In addition, the maximum recommended rate of correction at 24 and 48 hours was exceeded in 11 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/20\">",
"     20",
"    </a>",
"    ]. Inadvertent overcorrection was due to a water diuresis in 40 percent of patients which, as mentioned above, can occur when saline therapy corrects hypovolemia, thereby removing the hypovolemic stimulus to the release of antidiuretic hormone and permitting rapid excretion of the excess water. These limitations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38260?source=see_link\">",
"     \"Estimation of the sodium deficit in patients with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main use of the sodium deficit formula is to estimate the",
"    <strong>",
"     initial",
"    </strong>",
"    rate of sodium administration.",
"    <strong>",
"     Serial measurements",
"    </strong>",
"    of the serum sodium concentration are",
"    <strong>",
"     essential",
"    </strong>",
"    to assess the impact of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], beginning at two to three hours and then every three to four hours while active treatment is being given.",
"   </p>",
"   <p>",
"    Use of the sodium deficit formula to determine initial therapy can be illustrated by the following example. A nonedematous, mildly symptomatic woman who weighs 60 kg (approximately 50 percent of which is water) has a serum sodium concentration of 116",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The goal is to raise the serum sodium concentration by 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Rate of correction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sodium deficit (in meq) for initial therapy can be estimated from the above formula:",
"   </p>",
"   <p>",
"    &nbsp;Sodium deficit &nbsp;= &nbsp; TBW (0.5 &nbsp;x &nbsp;60 L) &nbsp;x &nbsp;desired change in serum sodium (122 &ndash; 116) &nbsp;= &nbsp; 180 meq",
"   </p>",
"   <p>",
"    The 180 meq of sodium can be given as 360 mL of hypertonic (3 percent) saline, which contains 513 meq of sodium per liter, or approximately 1 meq of sodium per 2 mL. This volume of hypertonic saline can be given at an initial rate of 20",
"    <span class=\"nowrap\">",
"     mL/h,",
"    </span>",
"    which would be expected to raise the serum sodium concentration at close to the desired rate of 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    during the first 24 hours which, as noted above, should be confirmed by serial measurements of the serum sodium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RATE OF CORRECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several general issues that must be addressed before discussing specific therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the hyponatremia acute or chronic?",
"     </li>",
"     <li>",
"      Does the patient have severe symptoms or intracranial pathology?",
"     </li>",
"     <li>",
"      What is the optimal rate of correction?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acute versus chronic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute hyponatremia are more likely to develop neurologic symptoms resulting from cerebral edema induced by water movement into the brain. However, the brain has a protective response that reduces the degree of cerebral edema; this response begins on the first day and is complete within several days. The net effect of this adaptation is that the clinical manifestations of hyponatremia are reduced, with the potential disadvantage of increasing the susceptibility to osmotic demyelination if there is overly rapid correction of the hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Symptomatic versus asymptomatic hyponatremia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some have suggested that hyponatremia developing over two or more days should be considered \"chronic.\" In practice, however, the duration of hyponatremia is often unknown, and patients with chronic hyponatremia may develop acute reductions in the serum sodium concentration. Thus, while the terms \"acute\" and \"chronic\" may be helpful conceptually, the clinical approach to the patient should be primarily determined by the severity of symptoms that are thought to be due to the hyponatremia and by the cause of the hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Symptomatic versus asymptomatic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe symptoms are most likely to occur with an acute (especially less than 24 hours) and marked reduction in the serum sodium concentration. Without time for the brain adaptation to occur, affected patients can develop severe neurologic manifestations, including seizures, impaired mental status or coma, and death (",
"    <a class=\"graphic graphic_figure graphicRef76471 \" href=\"UTD.htm?22/23/22909\">",
"     figure 1",
"    </a>",
"    ). These patients are typically treated initially with hypertonic saline. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Severe symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the brain adaptation that occurs over a few days, some patients with a serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    have less severe neurologic symptoms (eg, fatigue, nausea, dizziness, gait disturbances, forgetfulness, confusion, lethargy, and muscle cramps) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. These findings are",
"    <strong>",
"     not",
"    </strong>",
"    usually associated with impending herniation (as with acute severe hyponatremia) and do",
"    <strong>",
"     not",
"    </strong>",
"    mandate the urgent therapy recommended for patients with severe symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Mild to moderate symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to symptomatic patients, patients with chronic moderate hyponatremia (serum sodium concentration 120 to 130",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    have generally been considered to be at low risk for neurologic symptoms because of the less marked reduction in serum sodium concentration and the protective cerebral adaptation. However, some \"asymptomatic\" patients with moderate hyponatremia have subtle neurologic symptoms that may improve following elevation of the serum sodium concentration. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Mild to moderate symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Avoid overly rapid correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overly rapid correction of severe hyponatremia (serum sodium concentration almost always less than 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and usually less than 115",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can lead to a severe and sometimes irreversible neurologic disorder called the osmotic demyelination syndrome (formerly called central pontine myelinolysis, although demyelination may be more diffuse and does not necessarily involve the pons) (",
"    <a class=\"graphic graphic_figure graphicRef76471 \" href=\"UTD.htm?22/23/22909\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H7#H7\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Susceptibility of premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One group that is probably",
"    <strong>",
"     not",
"    </strong>",
"    at risk for this complication is patients with hyperacute hyponatremia that developed over a few hours due to a marked increase in water intake, as can occur in marathon runners, patients with primary polydipsia, and users of ecstasy. These patients have not had time for the brain adaptations that reduce the severity of brain swelling but also increase the risk of harm from rapid correction of the hyponatremia. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Acute versus chronic hyponatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Overly rapid correction of severe and more chronic hyponatremia can result from the too rapid or excessive administration of hypertonic saline or from elimination of the cause of impaired water excretion, such as the administration of saline to patients with true volume depletion and glucocorticoid therapy in adrenal insufficiency. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Treat the underlying disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255388087\">",
"    <span class=\"h4\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of osmotic demyelination syndrome have occurred in patients with severe hyponatremia in whom the serum sodium concentration increased by more than 10 to 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    within 24 hours or more than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/25,29\">",
"     25,29",
"    </a>",
"    ]. However, a few cases have been reported after correction by 9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because a 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    increase in serum sodium concentration appears to be sufficient to reverse the most severe manifestations of acute hyponatremia and because actual correction often exceeds what is intended, an increase of 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours is a reasonable therapeutic goal for all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, the goals of therapy are to raise the serum sodium concentration by 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and by",
"    <strong>",
"     less than 9",
"     <span class=\"nowrap\">",
"      meq/L",
"     </span>",
"    </strong>",
"    in any 24-hour period and",
"    <strong>",
"     less than 18",
"     <span class=\"nowrap\">",
"      meq/L",
"     </span>",
"    </strong>",
"    in any 48-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/1,3,30,31\">",
"     1,3,30,31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    For patients with severe symptoms, the first day's goal may be achieved in the first few hours since the daily rate rather than the hourly rate of correction is associated with osmotic demyelination.",
"   </p>",
"   <p>",
"    Issues related to the osmotic demyelination syndrome, including prevention and treatment with possible relowering of the serum sodium in patients who correct too rapidly, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, there are a variety of modalities used in the treatment of hyponatremia. The choice among them varies with the severity and underlying cause of the hyponatremia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Methods of raising the serum sodium'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With true volume depletion, the administration of saline can correct the hypovolemia, thereby removing the stimulus to the release of antidiuretic hormone (ADH) and allowing the excess water to be excreted in the urine. Correction of the underlying disorder can also be achieved with certain causes of SIADH (eg, glucocorticoids for adrenal insufficiency or the cessation of offending drugs). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Treat the underlying disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following discussion will provide an overview of the approach to therapy according to the presence or absence of symptoms that are attributable to the hyponatremia. The treatment of hyponatremia due to specific causes is discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For SIADH, in which the mainstay of chronic therapy is fluid restriction with, if necessary, the addition of oral salt tablets and, if the urine to serum electrolyte ratio is greater than 1 and the serum sodium concentration is below goal, a loop diuretic or vasopressin receptor antagonist (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For heart failure and cirrhosis, in which serum sodium concentrations below 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      are typically associated with close to end-stage disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H5#H5\">",
"       \"Hyponatremia in patients with heart failure\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H8#H8\">",
"       \"Hyponatremia in patients with cirrhosis\", section on 'Treatment'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For transurethral resection or hysteroscopy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link\">",
"       \"Hyponatremia following transurethral resection or hysteroscopy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic saline is warranted in patients with severe and often acute hyponatremia (serum sodium usually below 120",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    who present with seizures or other severe neurologic abnormalities (eg, impaired mental status) or with symptomatic hyponatremia in patients with intracerebral diseases that have been associated with brain herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/25,26,28,29,32,33\">",
"     25,26,28,29,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe symptoms of hyponatremia are most likely to occur in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise-associated hyponatremia, as in marathon runners (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link&amp;anchor=H19#H19\">",
"       \"Exercise-associated hyponatremia\", section on 'Use of hypertonic saline'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hyponatremia associated with the use of ecstasy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link&amp;anchor=H22#H22\">",
"       \"MDMA (ecstasy) intoxication\", section on 'Hyponatremia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link&amp;anchor=H23#H23\">",
"       \"MDMA (ecstasy) intoxication\", section on 'Seizures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Self-induced water intoxication in primary polydipsia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H14#H14\">",
"       \"Causes of hyponatremia\", section on 'Primary polydipsia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Postoperative hyponatremia due to SIADH in patients with known intracerebral pathology (eg, meningitis, stroke, or brain tumor) and in premenopausal women, who may be at increased risk of neurologic complications as compared with postmenopausal women and men. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H7#H7\">",
"       \"Manifestations of hyponatremia and hypernatremia\", section on 'Susceptibility of premenopausal women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary problem in patients who have seizures or other severe neurologic abnormalities is cerebral edema. Treatment of the hyponatremia must take into account two potential problems that can be associated with persistent neurologic deficits or death:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to adequately raise the serum sodium concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overly rapid correction of the hyponatremia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rate of correction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Avoid overly rapid correction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon broad clinical experience, the administration of",
"    <strong>",
"     hypertonic saline",
"    </strong>",
"    is the only rapid way to raise the serum sodium concentration and improve neurologic manifestations and outcomes in patients with severe symptomatic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/1,3,36-39\">",
"     1,3,36-39",
"    </a>",
"    ]. A small dose of hypertonic saline may also be given to selected symptomatic patients who develop hyponatremia and hypoosmolality during transurethral resection of the prostate or bladder or hysteroscopy. In this setting, the serum osmolality is not reduced to the same degree as the serum sodium due to the accumulation of glycine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    irrigation fluids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link&amp;anchor=H21#H21\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\", section on 'Role of hypertonic saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest a regimen that was first suggested for the treatment of hyponatremic athletes participating in endurance events such as marathon races. It consists of 100 mL of 3 percent saline given as an intravenous bolus, which should acutely raise the serum sodium concentration by 2 to 3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    thereby reducing the degree of cerebral edema; if severe neurologic symptoms persist or worsen, a 100 mL bolus of 3 percent saline can be repeated one or two more times at 10 minute intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/1,40,41\">",
"     1,40,41",
"    </a>",
"    ]. The rationale for this approach is that, in patients with symptomatic hyponatremia, rapid increases in serum sodium of approximately 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can reverse severe symptoms such as seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/1,4,42-44\">",
"     1,4,42-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link&amp;anchor=H19#H19\">",
"     \"Exercise-associated hyponatremia\", section on 'Use of hypertonic saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual goal for the overall 24-hour rate of correction is to raise the serum sodium by 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and by less than 9",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In patients with severe symptoms, this goal of increasing the serum sodium by 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can be achieved in the first six hours; the serum sodium can thereafter be maintained at a constant level for the remainder of the 24-hour period so as to avoid overly rapid correction. (See",
"    <a class=\"local\" href=\"#H255388087\">",
"     'Goals of therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Acute versus chronic hyponatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of symptomatic hyponatremia due to SIADH is complicated by the fact that, in patients with a high urine cation concentration, the initial elevation in the serum sodium induced by hypertonic saline will fall back toward baseline as the administered sodium is excreted in the urine. Why this occurs and recommendations for further therapy are discussed above and elsewhere. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'SIADH'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia developing in marathon runners, ecstasy users, or patients with primary polydipsia is associated with marked increases in fluid intake and, with exercise and ecstasy use, frequent failure to completely suppress ADH release. The net effect is acute hyponatremia that can develop over a period of several hours.",
"   </p>",
"   <p>",
"    Avoidance of overly rapid correction (&ge;9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period) is often difficult in patients with primary polydipsia. These patients tend to autocorrect since ADH is physiologically suppressed, permitting rapid excretion of large volumes of free water. Autocorrection can also occur in patients with exercise-associated hyponatremia or ecstasy use. Fortunately, the acute onset of hyponatremia in these disorders is associated with a low risk of osmotic demyelination due to overly rapid correction. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Avoid overly rapid correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    <strong>",
"     should not be given",
"    </strong>",
"    to these patients with self-induced water intoxication as a means to slow or reverse overcorrection. If such patients ingest water that cannot be excreted because of the antidiuretic effect of desmopressin, recurrent severe hyponatremia may ensue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mild to moderate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less severe neurologic symptoms that are attributable to hyponatremia (eg, dizziness, gait disturbances, forgetfulness, confusion, and lethargy) can be seen in patients with a serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    that develops over more than 48 hours, in patients with a lesser degree of hyponatremia that develops over less than 48 hours, and in patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    following discussion primarily applies to hyponatremia in patients with SIADH or volume depletion. Although mild to moderate symptoms due to hyponatremia can also occur in patients with heart failure or cirrhosis, serum sodium concentrations below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    are typically associated with close to end-stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Moderate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purposes of this discussion, moderate symptoms are defined as confusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lethargy. Some of these patients, particularly those with SIADH, may benefit from hypertonic saline, but do not require the aggressive approach suggested in the preceding section for those with severe neurologic symptoms. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Severe symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with SIADH and moderate symptoms, initial hypertonic saline therapy to raise the serum sodium at rates of 0.5 to 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per hour may be justified in the first four hours. This can generally be achieved by administering hypertonic (3 percent) saline at an initial rate of 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    lean body weight per hour. Such calculations are only estimates, and the serum sodium should be measured at two to three hours. Alternatively, therapy can begin with a 50 mL bolus of 3 percent saline followed by a slower rate of infusion. The total elevation in serum sodium during the first 24 hours should be 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and the same rate of increase should be continued on subsequent days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Mild to moderate symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of initial therapy in patients with moderate symptoms of hyponatremia who are volume depleted is more difficult. Isotonic saline will not rapidly raise the serum sodium until near euvolemia is attained and ADH secretion is suppressed. Hypertonic saline will raise the serum sodium immediately but, in some patients (particularly the elderly), the neurologic manifestations may not be clearly attributable to the hyponatremia. The optimal therapy in such patients must be made on an individual basis. Isotonic saline should be used in the vast majority of patients.",
"   </p>",
"   <p>",
"    Although hyponatremia is initially corrected slowly with isotonic saline in hypovolemic patients, ADH release will be appropriately suppressed once near euvolemia is restored. This will lead to a marked water diuresis and patients with an initial serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    might be at risk for overly rapid correction and possible osmotic demyelination. In such patients, if the serum sodium concentration has already increased by 4 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    but less than 9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the previous 24 hours, administration of dextrose in water to match urinary water losses will be required.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    can also be administered to diminish urinary water losses, making the administration of dextrose in water unnecessary. If, despite these efforts, overcorrection occurs, administration of desmopressin with dextrose in water to relower the serum sodium may be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mild or absent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SIADH or hypovolemia who have only mild symptoms (eg, dizziness, forgetfulness, gait disturbance) and a serum sodium above 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    should be treated with less aggressive therapy, such as fluid restriction and oral salt tablets or, in patients with hypovolemia, isotonic saline and treatment of the cause of fluid loss.",
"   </p>",
"   <p>",
"    If fluid restriction and salt tablets are not sufficient and the urine cation concentration is very high, subsequent therapy includes a loop diuretic or a vasopressin antagonist. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'SIADH'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who are hypovolemic, either intravenous isotonic saline or oral salt tablets may be effective in combination with treatment of the cause of hypovolemia.",
"   </p>",
"   <p>",
"    The treatment of asymptomatic hyponatremia in patients with heart failure and cirrhosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Necessity for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    are typically asymptomatic on routine history. Such patients have often been treated only with fluid restriction if the underlying disease (SIADH, heart failure, cirrhosis) cannot be corrected.",
"   </p>",
"   <p>",
"    However, some of these patients have subtle neurologic symptoms that can be improved by raising the serum sodium concentration. As an example, the SALT trials described above evaluated the effect of the vasopressin receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    compared with placebo in patients with chronic hyponatremia due to SIADH, heart failure, or cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/15\">",
"     15",
"    </a>",
"    ]. None of the patients had clinically apparent neurologic symptoms from hyponatremia and almost all had a serum sodium concentration of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher.",
"   </p>",
"   <p>",
"    Raising the serum sodium with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    resulted in statistically significant improvement on the Mental Component of the Medical Outcomes Study Short-Form General Health Survey at one month, a benefit that was significant only in patients with a serum sodium concentration between 120 and 129",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and was not seen in the placebo group. However, the benefit was usually not clinically significant and long-term efficacy is uncertain since the duration of follow-up was only 30 days. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Vasopressin receptor antagonists'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to subtle impairments in mentation, an increased incidence of falls due to impairments in gait and attention have been described in elderly patients with a serum sodium between 120 and 129",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    these manifestations may be improved by raising the serum sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/34/18986/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H6#H6\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Subtle manifestations in mild to moderate chronic hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations suggest that some and perhaps many apparently asymptomatic patients with moderate chronic hyponatremia (serum sodium 120 to 129",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    have subtle neurologic manifestations and that aiming for a goal serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or higher might be beneficial. Such an approach would apply",
"    <strong>",
"     only",
"    </strong>",
"    to patients with SIADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Asymptomatic hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Little benefit would be provided in patients with hyponatremia due to heart failure or cirrhosis in whom a serum sodium concentration persistently below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    is a marker of end-stage disease and a poor prognosis unless transplantation or some equivalent intervention is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia represents a relative excess of water in relation to sodium. It can be induced by an increase in water intake (primary polydipsia) or impaired water excretion. Impaired water excretion results from advanced renal failure or persistent release of antidiuretic hormone (ADH). ADH may be induced by effective volume depletion, the syndrome of inappropriate ADH secretion (SIADH), thiazide diuretics, adrenal insufficiency, or hypothyroidism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serum sodium concentration can be raised in hyponatremic patients by treating the underlying disease, restricting water intake, giving oral or intravenous sodium chloride, or by giving a vasopressin receptor antagonist. The choice of therapy is governed by the cause and severity of the hyponatremia and the presence or absence of neurologic symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Methods of raising the serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid restriction to below the level of urine output is indicated for hyponatremia in edematous states (such as heart failure and cirrhosis), the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and advanced renal failure. In general, fluid intake should be less than 800",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fluid restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sodium chloride, usually as isotonic saline or oral salt tablets, is given to patients with true volume depletion. The administered sodium and water initially corrects the hyponatremia (by approximately 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for every liter of isotonic saline infused) and then, once volume repletion is attained, by removing the stimulus to ADH release and allowing the excess water to be excreted. Salt therapy is generally contraindicated in edematous patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Sodium chloride administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When hyponatremia is corrected in patients with a serum sodium of 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less or with other comorbidities increasing the risk of osmotic demyelination (alcoholism, liver disease, malnutrition, or severe hypokalemia) and with the exception of patients with acute self-induced water intoxication, we recommend that the serum sodium concentration be increased by a goal of 4 to 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per 24 hours, and by less than 9",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in 24 hours",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in 48 hours, in order to help prevent osmotic demyelination (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Serial measurements of the serum sodium concentration are required to assess the impact of therapy, beginning at two to three hours and then every three to four hours while active treatment is being given. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Avoid overly rapid correction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with the severe symptoms (eg, seizures, severe neurologic abnormalities), the goal of increasing the serum sodium concentration by 4 to 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      can be achieved over a relatively short period of time (approximately six hours). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Avoid overly rapid correction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of initial therapy in patients with hyponatremia varies with the severity and cause of hyponatremia and the presence or absence of symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with severe symptomatic hyponatremia who present with seizures or other severe neurologic abnormalities or with symptomatic hyponatremia in patients with intracerebral diseases, we recommend urgent intervention with hypertonic saline rather than other therapies (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). An effective regimen is 100 mL of 3 percent saline given as an intravenous bolus, which should raise the serum sodium concentration by approximately 1.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in men and 2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in women, thereby reducing the degree of cerebral edema. If neurologic symptoms persist or worsen, a 100 mL bolus of 3 percent saline can be repeated one or two more times at ten minute intervals. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less severe neurologic symptoms that are attributable to hyponatremia (eg, dizziness, gait disturbances, forgetfulness, confusion, and lethargy) can be seen in patients with a serum sodium concentration below 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      that develops over more than 48 hours, in patients with a lesser degree of hyponatremia that develops over less than 48 hours, and in patients with chronic moderate hyponatremia (serum sodium 120 to 129",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      The approach varies with the severity of symptoms and the underlying cause of the hyponatremia:",
"     </li>",
"     <li>",
"      Among patients with SIADH who have moderate symptoms such as confusion and lethargy, we recommend the initial administration of hypertonic saline therapy to raise the serum sodium (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The goal is to raise the serum sodium 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour for three to four hours. The serum sodium should be measured at two to three hours, and subsequent infusion rate should be adjusted to achieve a rate of correction of 4 to 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day and correction by less than 9",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      within 24 hours and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      within 48 hours. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Moderate symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with moderate symptoms of hyponatremia who are volume depleted, the vast majority of patients should be treated with isotonic saline. Once most of the volume deficit has been repaired, ADH release will be appropriately suppressed, leading to the potential for overly rapid correction. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Moderate symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hypovolemia or SIADH who have only mild symptoms (eg, dizziness, forgetfulness, gait disturbance) should be treated with less aggressive therapy, such as isotonic saline in hypovolemia and, in SIADH, fluid restriction with, if necessary, the addition of oral salt tablets and, if the urine osmolality is more than twice the plasma osmolality and the serum sodium concentration is below goal, a loop diuretic. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Mild or absent symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among asymptomatic patients with moderate hyponatremia, the treatment varies with the underlying cause of the hyponatremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For asymptomatic patients with moderate chronic hyponatremia (serum sodium 120 to 129",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      resulting from SIADH, we suggest initiating treatment with fluid restriction if the urine to serum electrolyte ratio is less than 0.5 (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Necessity for therapy'",
"      </a>",
"      above.) Most patients will respond to fluid restriction of 800",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"      We aim for a goal serum sodium of 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher. Among patients with a urine to serum electrolyte ratio greater than 1, in whom fluid restriction will not be sufficient to achieve the desired goal, subsequent therapy includes fluid restriction with salt tablets and, if necessary, a loop diuretic or, alternatively, a vasopressin antagonist without fluid restriction.",
"     </li>",
"     <li>",
"      Among asymptomatic patients who are hypovolemic, either intravenous isotonic saline or oral salt tablets may be effective in combination with treatment of the cause of hypovolemia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Symptomatic versus asymptomatic hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of asymptomatic hyponatremia in patients with heart failure and cirrhosis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"       \"Hyponatremia in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"       \"Hyponatremia in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasopressin receptor antagonists are an alternative or possible addition to fluid restriction or sodium chloride administration in patients with hyponatremia. Only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      (oral) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"       conivaptan",
"      </a>",
"      (intravenous) are currently available in the United States. Both drugs are approved for the management of patients with euvolemic hyponatremia, mostly due to SIADH. Tolvaptan is also approved for use in patients with heart failure or cirrhosis. There are important limitations to the use of oral tolvaptan and conivaptan should not be used in patients with cirrhosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Vasopressin receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vasopressin receptor antagonists should",
"      <strong>",
"       not",
"      </strong>",
"      be used in hyponatremic patients who are volume depleted in whom volume repletion is the primary therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/1\">",
"      Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009; 29:282.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.716.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/3\">",
"      Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/4\">",
"      Adrogu&eacute; HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/5\">",
"      Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/6\">",
"      Oh MS, Uribarri J, Barrido D, et al. Danger of central pontine myelinolysis in hypotonic dehydration and recommendation for treatment. Am J Med Sci 1989; 298:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/7\">",
"      Kamel KS, Bear RA. Treatment of hyponatremia: a quantitative analysis. Am J Kidney Dis 1993; 21:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/8\">",
"      EDELMAN IS, LEIBMAN J. Anatomy of body water and electrolytes. Am J Med 1959; 27:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/9\">",
"      Steele A, Gowrishankar M, Abrahamson S, et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997; 126:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/10\">",
"      Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000; 319:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/11\">",
"      LARAGH JH. The effect of potassium chloride on hyponatremia. J Clin Invest 1954; 33:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/12\">",
"      Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatremia. Ann Intern Med 1971; 75:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/13\">",
"      Berl T, Rastegar A. A patient with severe hyponatremia and hypokalemia: osmotic demyelination following potassium repletion. Am J Kidney Dis 2010; 55:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/14\">",
"      Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/15\">",
"      Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/16\">",
"      Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/17\">",
"      Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/18\">",
"      Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.",
"     </a>",
"    </li>",
"    <li>",
"     Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/20\">",
"      Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007; 2:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/21\">",
"      Berl T. The Adrogue-Madias formula revisited. Clin J Am Soc Nephrol 2007; 2:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/22\">",
"      Mount DB. The brain in hyponatremia: both culprit and victim. Semin Nephrol 2009; 29:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/23\">",
"      Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006; 119:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/24\">",
"      Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc 2004; 96:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/25\">",
"      Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases. Ann Intern Med 1987; 107:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/26\">",
"      Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/27\">",
"      Soupart A, Penninckx R, Stenuit A, et al. Treatment of chronic hyponatremia in rats by intravenous saline: comparison of rate versus magnitude of correction. Kidney Int 1992; 41:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/28\">",
"      Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992; 117:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/29\">",
"      Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine (Baltimore) 1993; 72:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/30\">",
"      Adrogu&eacute; HJ, Madias NE. The challenge of hyponatremia. J Am Soc Nephrol 2012; 23:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/31\">",
"      Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/32\">",
"      Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 2003; 18:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/33\">",
"      Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int 1990; 37:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/34\">",
"      Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999; 281:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/35\">",
"      Nzerue CM, Baffoe-Bonnie H, You W, et al. Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc 2003; 95:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/36\">",
"      Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 1996; 46:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/37\">",
"      Ayus JC, Krothapalli RK, Arieff AI. Changing concepts in treatment of severe symptomatic hyponatremia. Rapid correction and possible relation to central pontine myelinolysis. Am J Med 1985; 78:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/38\">",
"      Gross P, Reimann D, Neidel J, et al. The treatment of severe hyponatremia. Kidney Int Suppl 1998; 64:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/39\">",
"      Arieff AI, Ayus JC. Endometrial ablation complicated by fatal hyponatremic encephalopathy. JAMA 1993; 270:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/40\">",
"      Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners. N Engl J Med 2005; 353:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/41\">",
"      Hew-Butler T, Ayus JC, Kipps C, et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med 2008; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/42\">",
"      Sarnaik AP, Meert K, Hackbarth R, Fleischmann L. Management of hyponatremic seizures in children with hypertonic saline: a safe and effective strategy. Crit Care Med 1991; 19:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/43\">",
"      Worthley LI, Thomas PD. Treatment of hyponatraemic seizures with intravenous 29.2% saline. Br Med J (Clin Res Ed) 1986; 292:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/44\">",
"      Siegel AJ, Verbalis JG, Clement S, et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007; 120:461.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/34/18986/abstract/45\">",
"      Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2350 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18986=[""].join("\n");
var outline_f18_34_18986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODS OF RAISING THE SERUM SODIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treat the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sodium chloride administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - True volume depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H168163314\">",
"      Equation to estimate efficacy of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - SIADH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect of potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ESTIMATION OF THE SODIUM DEFICIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RATE OF CORRECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acute versus chronic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Symptomatic versus asymptomatic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Avoid overly rapid correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H255388087\">",
"      Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mild to moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mild or absent symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Necessity for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2350|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/23/22909\" title=\"figure 1\">",
"      Hyponatremia demyelination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38260?source=related_link\">",
"      Estimation of the sodium deficit in patients with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=related_link\">",
"      Exercise-associated hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_34_18987="Volumes of hemodialysis lines based on patient weight";
var content_f18_34_18987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Volumes of hemodialysis lines based on patient weight",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patient wt (kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Venous (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arterial (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total (mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mini-neonatal",
"       </td>",
"       <td>",
"        &lt;6",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal",
"       </td>",
"       <td>",
"        6-12",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediatric",
"       </td>",
"       <td>",
"        &gt;12",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult",
"       </td>",
"       <td>",
"        &gt;30",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        132",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18987=[""].join("\n");
var outline_f18_34_18987=null;
var title_f18_34_18988="History and LRs for MI";
var content_f18_34_18988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood ratios for myocardial infarction (MI) based on components of the chest pain history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Description of pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive likelihood ratio (95%",
"CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Descriptions",
"increasing the likelihood of MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation to right arm or shoulder",
"       </td>",
"       <td>",
"        4.7 (1.9-12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation to both arms or shoulders",
"       </td>",
"       <td>",
"        4.1 (2.5-6.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exertional",
"       </td>",
"       <td>",
"        2.4 (1.5-3.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation to left arm",
"       </td>",
"       <td>",
"        2.3 (1.7-3.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated with diaphoresis",
"       </td>",
"       <td>",
"        2.0 (1.9-2.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated with nausea or vomiting",
"       </td>",
"       <td>",
"        1.9 (1.7-2.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Worse than previous angina or similar to previous MI",
"       </td>",
"       <td>",
"        1.8 (1.6-2.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Described as pressure",
"       </td>",
"       <td>",
"        1.3 (1.2-1.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Descriptions",
"decreasing the likelihood of MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleuritic",
"       </td>",
"       <td>",
"        0.2 (0.1-0.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Positional",
"       </td>",
"       <td>",
"        0.3 (0.2-0.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sharp",
"       </td>",
"       <td>",
"        0.3 (0.2-0.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reproducible with palpation",
"       </td>",
"       <td>",
"        0.3 (0.2-0.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inframammary location",
"       </td>",
"       <td>",
"        0.8 (0.7-0.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonexertional",
"       </td>",
"       <td>",
"        0.8 (0.6-0.9)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CI: confidence interval.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Swap, C, Nagurney, J. Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA 2005; 294:2623.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18988=[""].join("\n");
var outline_f18_34_18988=null;
var title_f18_34_18989="Age pulmonary histiocytosis X";
var content_f18_34_18989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Age at onset of pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The data shown were obtained from published papers in which the age at onset of symptoms or diagnosis could be determined (total number of subjects = 168). The peak age at onset is between 20 and 40.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18989=[""].join("\n");
var outline_f18_34_18989=null;
var title_f18_34_18990="Contents: Heart transplantation";
var content_f18_34_18990=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Heart transplantation",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Heart transplantation",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28040\">",
"           Acute cardiac allograft rejection: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/6/14441\">",
"           Acute cardiac allograft rejection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/1/23576\">",
"           Arrhythmias following cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12505\">",
"           Clinical manifestations and diagnosis of acute renal allograft rejection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29738\">",
"           Cytomegalovirus infection in renal transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34170\">",
"           Development of malignancy following solid organ transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/63/31738\">",
"           Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/16/25862\">",
"           Left ventricular dysfunction after orthotopic cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/25000\">",
"           Lipid abnormalities after cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/9/18585\">",
"           Natural history and diagnosis of cardiac allograft vasculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/25/44441\">",
"           Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/12/42184\">",
"           Prevention and treatment of cardiac allograft vasculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23338\">",
"           Treatment and prevention of post-transplant lymphoproliferative disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Indications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/31/34297\">",
"           Indications and contraindications for cardiac transplantation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/62/31718\">",
"           Evaluation for infection before solid organ transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23306\">",
"           Immunizations in solid organ transplant candidates and recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/47/29433\">",
"           Infection in the solid organ transplant recipient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10714\">",
"           Prophylaxis of infections in solid organ transplantation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/6/99\">",
"           Heart-lung transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/0/20487\">",
"           Pregnancy after cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/15/22775\">",
"           Prognosis after cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15321\">",
"           Solid organ transplantation in HIV-infected individuals",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/6/14441\">",
"           Acute cardiac allograft rejection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/61/41945\">",
"           Cyclosporine and tacrolimus nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18458\">",
"           Induction and maintenance of immunosuppressive therapy in cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28090\">",
"           Pharmacology and side effects of cyclosporine and tacrolimus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/12/42184\">",
"           Prevention and treatment of cardiac allograft vasculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/38/7783\">",
"           Rehabilitation after cardiac transplantation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-7E0AAD4337-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f18_34_18990=[""].join("\n");
var outline_f18_34_18990=null;
var title_f18_34_18991="Gram stain sputum 3B answer";
var content_f18_34_18991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcus aureus on blood agar plate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The moderate-sized golden beige colonies are characteristic of Staphylococcus aureus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_34_18991=[""].join("\n");
var outline_f18_34_18991=null;
